# Beta lactam compound and a pharmaceutical composition containing the same.

## Abstract
β lactam compounds represented by the general formula

## Claims
What is Claimed is 1. A ss lactam compound represented by the general formula EMI78.1 wherein Acyl represents EMI78.2 where R1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a substituted lower alkyl group having 1 to 6 carbon atoms where the substituent is a cyano group, a halogen atom, a carboxyl group, a lower alt7caXonyl group having 2 to 6 carbon atoms, or a carbamoyl group , or a group represented by EMI78.3 where R2 and R3 are same or different, and represent hydrogen atoms, lower alkyl groups having 1 to 5 carbon atoms, or a 3 to 6 membered cycloalkylidene group with the carbon atoms bonded thereto A represents a phenyl or naphtyl group respectively substituted by OR4 n and further optionally substituted by other group s R4 represents a hydrogen atom, or a lower alkanoyl group having 1 to 5 carbon atoms Q and m represent 0 or 1 n represents an integer of 1 to 4 , orEMI79.1 where 9 epresents a hydrogen atom, a lower alkanoyl group having 1 to 5 carbon atoms, a carbamoyl group, a lower alkyl group having 1 to 5 carbon atoms, a carbamoyl group substituted by a lower alkanoyl group having 1 to 5 carbon atoms, or a group represented by EMI79.2 where R2 R3, A, R4, Q and n have the same meanings as defined above X represents a methoxy group, an azide group, an amino group, NHCOR6 where R6 a lower represents alkyl group having 1 to 5 carbon atoms, an amino group, or a lower alkylamino group having 1 to 5 carbon atoms, S R where R7 represents a substituted or unsubstituted 5 or 6 membered monocyclic or bicyclic heterocyclic group having 1 to 5 nitrogen, oxygen or sulfur atoms , a pyridinium group, or a substituted pyridinium group and R represents a hydrogen atom, an alkali metal, an alkaline earth metal, an organic ammonium group or an ester residue readily hydrolyzable in vivo. In spite of the above definition, when X is a methoxy group, R1 is a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, or a substituted lower alkyl group having 1 to 6 carbon atoms where the substituent is a cyano group, a halogen atom, or a carbamoyl group nd a pharmacologically acceptable acid or base addition salt thereof. 2. A compound according to claim 1 wherein Acyl isEMI80.1 where Rla represents a lower alkyl group having 1 to 6 carbon atoms, a lower alkyl group having 1 to 6 carbon atoms substituted by a carboxyl group, orEMI80.2 wherein R2a and R2b are same or different, and represent hydrogen atoms or lower alkyl groups having 1 to 5 carbon atoms, and R4, t and n have the same meanings as defined above , orEMI80.3 where n has the same meaning as defined above and X is an azido group, an amino group, NHCOR6 where R6 has the same meaning as defined above , S R7a where R7a represents a 5 or 6 membered monocyclic or bicyclic heterocyclic group having 1 to 4 nitrogen, or 1 to 3 nitrogen and one sulfur atoms optionally substituted by a lower alkyl group having 1 to 5 carbon atoms, an amino group, a phenyl group, CH2 qCO2H where q has the same meaning as defined above or a phenyl group, or a pyridinium group. 3. A compound according to claim 2 wherein said heterocyclic group in respect of R7a is selected from a pyrrolyl group, an imidazolyl group, a pyrazinyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a triazolyl group, a tetrazolyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group and a benzothiazolyl group. 4. A compound according to claim 2 wherein R is a hydrogen atom, an alkali metal or an alkaline earth metal. 5. A B lactam compound represented by the general formula EMI81.1 wherein Y represents an amino group, a phthalimido group or a phenylacetamido group X has the same meaning as defined above and R has the same meaning as R defined above or further represents a carboxyl protecting group and an acid addition salt thereof in case of Y being anaminogroup. 6. A compound according to claim 5 wherein said carboxyl protecting group is selected from a t butyl, benzyl, p nitrobenzyl, benzhydryl, trityl and trialkylsilyl group. 7. An antimicrobial pharmaceutical composition which comprises an effective antimicrobial amount of a compound according to any of claims 1 to 4 and at least one member of the group consisting of pharmaceutically acceptable diluents, carriers and adjuvants.

## Description
TITLE OF INVENTION B LACTAM COMPOUND AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAMERelated Applications The present invention is related generally to the invention disclosed in U.S. Patent Application SN 419,513 filed on September 17, 1982 or European Patent ApplicationNo. 82 108606.3 , and U.S. Patent Application SN filed on September 27, 1982 or European Patent ApplicationNo. 82 109004.0 .Background of the Invention The present invention relates to a ss lactam compound, more specifically to a carbacephem compound wherein an amino group at 7 position is acylated with a 2 2 amino thiazol 4 yl 2 syn methoxyimino acetyl group or 2 2 amino thiazol 4 yl 2 amino acetyl group, or a related group thereof, and hydrogen atom at 4 position is substituted by a specific group, a related compound thereof, and a pharmaceutical composition containing said carbacephem compound. Many ss lactam antibiotics have been and are under development in order to provide good chemical medicaments for curing various microbial infections. Among those compounds, carbacephem compounds wherein an amino group at 7 position is acylated with 2 2 aminothiazol 4 yl 2 synmethoxyimino acetyl group or a related group thereof, and hydrogen atom at 4 position is substituted by a bromine atom, a methyl group, an acetoxy group or a hydroxyl group, and an intermediate thereof have been known GB 2017103A,GB 2017102A, EP 0025602A1, EP 0027882A1, EP 0014475A1,EP 0014476A1, etc. . Further, some 2 substituted 3 cephem compounds have been known. That is, 2 methoxy substituted one is disclosed inJOC 41, 2150 1976 and 2 azido substituted one in JapanesePublished Unexamined Patent Application No. 646590 1980. The S lactam compounds of the present invention have a strong anti microbial activities against a wide range of Gram positive and Gram negative bacteria.Detailed Description of the Invention This invention relates to a novel S lactam compound represented by the general formula I EMI2.1 wherein Acyl represents EMI2.2 where R1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a substituted lower alkyl group having 1 to 6 carbon atoms where the substituent is a cyano group, a halogen atom, a carboxyl group, a lower alkoxycarbonyl group having 2 to 6 carbom atoms, or a carbamoyl group , or a group representea by EMI2.3 where R2 and R3 are same or different, and represent hydrogen atoms, lower alkyl groups having 1 to 5 carbon atoms, or a 3 to 6 membered cycloalkylidene group with the carbon atoms bonded thereto A represents a phenyl or naphthyl group respectively substituted by OR4 n and further optionally substituted by other group s R4 represents a hydrogen atom, or a lower alkanoyl group having 1 to 5 carbon atoms Q and m represent 0 or 1 n represents an integer of 1 to 4 1, orEMI3.1 where R5 represents a hydrogen atom, a lower alkanoyl group having 1 to 5 carbon atoms, a carbamoyl group, a lower alkyl group having 1 to 5 carbon atoms, a carbamoyl group substituted by a lower alkanoyl group having 1 to 5 carbon atoms, or a group represented by EMI3.2 where R2, R3, A, R4, Q and n have the same meanings as defined above X represents a methoxy group, an azide group, an amino group, NHCOR6 where R6 represents a lower alkyl group having 1 to 5 carbon atoms, an amino group, or a lower alkylamino group having 1 to 5 carbon atoms , S R7 where R7 represents a substituted or unsubstituted 5 or 6 membered monocyclic or bicyclic heterocyclic group having 1 to 5 nitrogen, oxygen or sulfur atoms , a pyridinium group, or a substituted pyridinium group and R represents a hydrogen atom, an alkali metal, an alkaline earth metal, an organic ammonium group or an ester residue readily hydrolyzable in vivo.In spite of the above definition, when X is a methoxy group,R1 is a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, or a substituted lower alkyl group having 1 to 6 carbon atoms where the substituent is a cyano group, a halogen atom, or a carbamoyl gróup . hereinafter referred to as Compound I . The same rule is applied to a compound of other formula and its pharmacologically acceptable acid or base addition salt. Compound I and a salt thereof have an antimicrobial activity as above mentioned. The present invention also relates to a ss lactam compound represented by the general formula II EMI4.1 wherein Y represents an amino group, a phthalimido group or a phenylacetamido group, X has the same meaning as defined above, and R has the same meaning as R or further represents a carboxyl protecting group and an acid addition salt thereof in case of Y being an amino group. Compound II is useful as an intermediate for I preparation of Compound I . On the substituent in substituted lower alkyl having 1 to 6 carbon atoms in the definition of R1 in the general formula I , halogen atom includes chlorine atom, bromine atom, etc., and a lower alkoxycarbonyl having 2 to 6 carbon atoms includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc. Further, 3 to 6 membered cycloalkylidene group in the definition of R2 and R3 includes cyclopropylidene, cyclobutylidene, cyclopentylidene, cyclohexylidene, etc. The substituent on A other than OR4 n is exemplified by a lower alkyl group having 1 to 5 carbon atoms, a lower alkoxy group having 1 to 5 carbon atoms, an oxo group, an amino group, a nitro group, CH2 qCO2H, CH2 qSO3H, CH2 qN lower alkyl group 2, etc., where q represents an integer of 1 to 3 and lower alkyl group represents one having 1 to 4 carbon atoms. The lower alkylamino group having 1 to 5 carbon atoms in the definition of R6 is exemplified by methylamino, ethylamino, n propylamino, etc.Further, 5 or 6 membered monocyclic or bicyclic heterocyclic group in the definition of R7 is exemplified by a furyl group, a thienyl group, a pyrrolyl group, an oxazolyl group, an isoxazolyl group, an imidazolyl group, a pyrazinyl group, a thiazolyl group, a thiazolinyl group, an isothiazolyl group, a thiadiazolyl group, a triazolyl group, a tetrazolyl group, a lH pyranyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a beniothiazolyl group, etc. The substituent thereon is exemplified by a lower alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a lower alkanoyloxy group having 1 to 5 carbon atoms, a hydroxyl group, an oxo group, an amino group, a nitro group, a phenyl group, CH2 gCO2H, CH2 qSO3H, CH2 qN lower alkyl group 2, etc., where q has the same definition as above and the lower alkyl group represents one having 1 to 4 carbon atoms. A substituted or unsubstituted 5 or 6 membered monocyclic or bicyclic heterocyclic group having 1 to 4 nitrogen, or 1 to 3 nitrogen and one sulfur atoms is especially preferable as the heterocyclic group. The substituent on the substituted pyridinium group in the definition of R7 is exemplified by a carbamoyl group, a carboxyl groups a cyano group, etc. The alkali metal and the alkaline earth metal for the group R are exemplified by sodium, potassium, magnesium, calcium, barium, etc. The organic ammonium group for the group R includes ammonium groups or organic amines such as basic amino acids. The ester residue readily dissociable in vivo in the definition of R is exemplified by a group represented by the formula EMI6.1 where R8 represents a hydrogen atom or a lower alkyl group having 1 to 6 carbon atoms, and Rg represents a lower alkyl group having 1 to 6 carbon atoms or a phenyl group , a group represented by the formula EMI6.2 etc. Further, the lower alkyl group in the definition of various groups in the general formula I is exemplified by methyl, ethyl, n propyl, i propyl, n butyl, i butyl, sec butyl, t butyl, n pentyl, n hexyl, etc. The lower alkanoyl group in the definition of various groups in the general formula I is exemplfied by formyl, acetyl, propionyl, n butyryl, etc.The carboxyl protecting group in the definition of R in the general formula II is exemplified by t butyl, benzyl, p nitrobenzyl, benzhydryl, trityl, trialkylsilyl such as trimethylsilyl and triethylsilyl, etc. The pharmaceutically acceptable acid or base addition salt of Compound I means a salt in respect of a basic group such as an amino group, or a salt in respect of an acidic group such as a carboxyl group except of that at 2 position. As the base addition salt, the same salts as mentioned in respect of R are exemplified, and as the acid addition salt, hydrochloride, hydrobromide, nitrate, sulfate, phosphate, acetate, benzoate, maleate, fumarate, succinate, tartrate, citrate, oxalate, methanesulfonate, benzenesulfonate, etc. are exemplified. Acid addition salts of Compound II includes a salt with an inorganic acid or with an organic acid and are exemplified by hydrochloride, hydrobromide, phosphate, trifluoroacetate, methanesulfonate, etc. Compound I can be prepared according to the following two processes.Process A A carbacephem compound represented by the general formula II 1 EMI7.1 wherein X and R have the same meanings as defined above is reacted with a reactive derivative of a carboxylic acid represented by the general formula III EMI7.2 where Z represents an amino group, or an amino group protected by a trityl group, a formyl group, a chloroacetyl group, a bromoacetyl group, a 2,2,2 trichloroacetyl group, a t butyloxycarbonyl group, a benzyloxycarbonyl group, etc. R4 has the same meaning as R4, or further represents a hydroxyl protecting group such as a chloroacetyl group, a bromoacetyl group, a 2,2,2 trichloroethoxycarbonyl group, a tetrahydropyranyl group, a methoxymethyl group, an ethoxyethyl group, a trimethylsilyl group and a t butyldimethylsilyl group R2, R3, A, Q and n have the same meanings as defined above , or by the general formula IV EMI8.1 where Z and R5 have the same meanings as defined above to prepare a compound represented by the general formula V EMI8.2 where Z, X, R , R2, R3, R41 , A, Q and n have the same meanings as defined above , or by the general formula VI EMI8.3 where Z, X, R5 and R have the same meanings as defined above , and then the resulting compound is subjected to removal of the protective group to prepare a compound represented by the general formula In1 EMI9.1 wherein X, R, R2, R3, R4, A, Q and n have the same meanings as defined above or by the general formula I 2 EMI9.2 wherein X, R and R5 have the same meanings as defined above . Compound II 1 , and Compounds 1 1 and I 2 are contained respectively in Compound II and Compound I . The reactive derivative of carboxylic acid .represented by the general formulae III and IV is exemplified by an acid halide such as acid chloride and acid bromide, an acid anhydride including one formed from Compound III or IV with dicyclohexylcarbodiimide , a mixed acid anhydride such as one with a chlorocarbonic ester, e.g. methyl chlorocarbonate, ethyl chlorocarbonate, isobutyl chlorocarbonate, etc., an acid azide, an active ester such as nitrophenylthio ester and N hydroxysuccinic acid ester, etc. The ordinary method for acylation of penicillin and cephalosporin is applicable to the reaction using the said reactive derivative of carboxylic acid.The Compound II 1 can be used as such, or as an inorganic salt such as a hydrochloride, a hydrobromide and a phosphate, or as an organic acid salt such as a trifluoroacetate and a methanesulfonate, or as an N sily derivative. The acylation reaction is carried out in an aqueous or non aqueous solvent at a temperature of 50 to 500 C, if necessary, in the presence of a base or other acid capturing agent. Usable as the solvent are halogenated hydrocarbons such as methylene chloride, etc., ethers such as tetrahydrofuran and dioxane, esters such as ethyl acetate, etc., amides such as dimethylformamide, etc., sulfoxides such as dimethylsulfoxide, etc., acetonitrile, acetone and water alone or in combination. Usable as the base are organic tertiary amines such as triethylamine, dimethylaniline, etc. and inorganic bases such as sodium hydrogen carbonate, potassium carbonate, etc., and usable as the other acid capturing agent are oxirane compounds such as ethylene oxide, propylene oxide, etc. In the step of removing the protective group to obtain Compound In1 or I 2 , the protective group for the functional groups amino group, hydroxyl group and carboxyl group in Z, R and R can be removed from 4 Compound V or VI , which is an intermediate, according to the ordinary method after isolation and purification thereof, or without the isolation and purification. An appropriate method for removing the respective protective group for the hydroxyl group, amino group and carboxyl group can be applied according to the detailed description of Protective Groups in Organic Chemistry 1973, PlenumPress , Chapters 2, 3, 4 and 5, compiled by McOmie. Process B A compound represented by the general formula VII EMI11.1 where Z and R have the same meanings as defined above, and R1 has the same meaning as R1 or further representsR1 where a carboxyl group or a hydroxyl group, when contained, is protected by a respective protecting group is converted to a compound represented by the general formula VIII EMI11.2 where X represents a halogen atom, a methanesulfonyloxy group, a p toluenesulfonyloxy group, an acetoxy group or a chloroacetoxy group, and Z, R and R1, have the same meanings as defined above , which then may be isolated if desired, but is generally subjected, without isolation, to the successive substitution reaction step to obtain a compound represented by the general formula IX EMI11.3 wherein Z, X, R and R1 have the same meanings as defined above , which then may be isolated if desired, but is generally subjected, without isolation, to the successive step of removing the protective group to prepare a compound represented by the general formula I 3 EMI12.1 where X, R and R1 have the same meanings as defined above .Compound I 3 is contained in Compound I . Compound VII and a method for preparation thereof are disclosed in EP 0025602A1. On R1,, the carboxyl protecting group and hydroxyl protecting group are exemplified by the same one as exemplified respectively on R and R4 . The preparation of Compound VIII can be carried out by the ordinary reagent under the ordinary reaction conditions for halogenating, mesylating, tosylating, acetylating or chloroacetylating a hydroxyl group.Particularly specific examples of the reagent include triphenylphosphine N bromosuccimide, triphenylphosphinebromine, triphenylphosphine chlorine, trialkyl phosphite or triaryl phosphite halogen molecule, phosphorus trichloride, phosphorus tribromide, methanesulfonyl chlorideLiBr, LiCl or LiI, N chlorosuccimidedimethyl sulfide, methanesul fonyl chloride, p toluenesulfonyl chloride, acetyl chloride, chloroacetyl chloride, acetic anhydride, etc. The step is carried out in an aqueous or non aqueous solvent at a temperature of 50 to 100 C, if necessary, in the presence of a base or other acid capturing agent.The solvent includes halogenated hydrocarbons such as methylene chloride, etc., ethers such as tetrahydrofuran and dioxane, esters such as ethyl acetate, etc., amides such as dimethylformamide, etc., sulfoxides such as dimethylsulfoxide, etc., acetonitrile, acetone or water alone or in combination. Usable as the base are organic amines such as triethylamine, dimethylaniline, pyridine,S collidine, etc. and inorganic bases such as sodium hydrogen carbonate, etc. The same acid capturing agents as used in the preparation of Compound V or VI are usable as other acid capturing agents. The substitution reaction to Compound IX can be carried out by reacting Compound VIII with a nucleophilic reagent. That is, the reaction is carried out using a heterocyclic thiol, an optionally substituted pyridine, sodium azide or methanol as the nucleophilic reagent in the presence or absence of a protic acid such as hydrogen bromide, hydrogen chloride and p toluenesulfonic acid, or a Lewis acid such as zinc chloride, aluminum chloride, tin chloride and titanium tetrachloride. The reaction is also carried out using a heterocyclic thiol in the absence or, if necessary presence of a base such as potassium carbonate, sodium hydrogen carbonate, silver carbonate, silver oxide, sodium hydride and an organic amine, e.g. triethylamine, pyridine, etc. Similar solvents and temperature to those in the step of preparing the Compound VIII can be adopted in appropriate selection. In respect of the stereochemistry of substituentX there are two types, i.e. form cis to 7 acyl group and a form trans to 7 acyl group , and one type can be more or substantially selectively synthesized by selecting the said reaction conditions. The step of removing the protective group can be carried out by removing the protective group for the functional groups amino group, hydroxyl group and carboxyl group in Z, R and R according to the ordinary procedure, thereby obtaining Compound I 3 . An appropriate method for the respective protective group for the hydroxyl group, amino group and carboxyl group is applied to the removal of the protective group. Such a method is detailedly described in Protective Groups inOrganic Chemistry 1973, Plenum Press , Chapters 2, 3, 4 and 5, compiled by McOmie. Compound II is a new intermediate for preparation of Compound I and can be prepared according to the following steps.EMI14.1 EMI15.1 where R represents a carboxyl protecting group Compounds IIa to IIh are contained in Compound II . The same carboxyl protecting groups as exemplified for R are exemplified as R . Compound IIc, IId, Ile or IIh can be reacted with a hydroxide or a carbonate of alkali metal or alkaline earth metal, an organic amine,EMI15.2 etc. according to an ordinary acid base reaction or esterification to prepare Compound II or Compound II 1 whereR is R. Compound X is a starting compound and can be prepared according to a method disclosed in GB 2017102A,Japanese Published Unexamined Patent Application No. 91991 1982, etc. A specific example for preparation of a Compound X is also disclosed in Reference Examples. The step X IIa is a treatment with a halogenating agent used in halogenation of an aryl position such as N halosuccinimide, for example, N bromosuccinimide, etc., N haloacetamide bromide1 pyrrolidone hydrotribromide, etc.The used solvent is preferably a halogenated hydrocarbon such as dichloromethane, chloroform, carbon tetrachloride, etc. The reaction is carried out at a temperature from room temperature to the reflux temperature of the solvent to be used. A good result can be obtained when the reaction is carried out in the presence of a catalyst such as perbenzoic acid, azobisisobutyronitrile, etc. The thus obtained halogen derivative can be converted to a Compound IIa by reacting it with various nucleophilic agents represented by HX. The convertion is carried out using a heterocyclic thiol, an optionally substituted pyridine, sodium azide or methanol as the nucleophilic reagent in the presence or absence of a protic acid such as hydrogen bromide, hydrogen chloride and p toluenesulfonic acid, or a Lewis acid such as zinc chloride, aluminum chloride, tin chloride and titanium tetrachloride. The conversion is also carried out using a heterocyclic thiol in the absence or, if necessary presence of a base such as potassium carbonate, sodium hydrogen carbonate, silver carbonate, silver oxide, sodium hydride and an organic amine, e.g. triethylamine, pyridine, etc. The solvent for use in the conversion includes an aprotic solvent, for example, a halogenated solvent such as methylene chloride, chloroform, and carbon tetrachloride, an ether solvent such as tetrahydrofuran, dioxane, etc., an ester solvent such as ethyl acetate, etc., an aprotic polar solvent such as dimethylformamide, dimethylsulfoxide, and hexamethylphosphoramide, acetone, cetonitrile, etc.The solvents can be used alone or in mixture. The conversion is carried out at 200C to 1000 C. According to the stereochemistry of group X, there are two types, that is, cis type form and trans type a form with respect to the 7 position phthallmido group, and it is possible to synthesize one type more than the other or to selectively synthesize substantially one type by selecting the said reaction conditions. The dephthalization step Ia Ib and If Ic can be carried out according to the process disclosed in J.Am. Chem. Soc. 97 5582 1975 , which is carried out in three steps as given below, and it is also possible to carry out hydrazinolysis in one step, depending upon selection of the conditions.EMI17.1 The step for elimination of R , IIb IIc , IIa IIf or IIg IIh can be carried out according to the process disclosed in detail in Protective Groups in Organic Chemistry compiled by McOmie 1973, PlenumPress ,Chapter 5. Particularly preferable acid includes trifluoroacetic acid, formic acid, hydrochloric acid acetic acid, hydrogen chloride, etc. The solvent includes ethyl acetate, methylene chloride, anisol, etc. and can be used alone or in mixture. The reaction can be carried out in the absence of the solvent. The reaction is carried out at a temperature from 100C to 600C. The phenylacetylation step IIc B IId and IIb lIg can be carried out by acylation reaction according to the ordinary acid chloride process using phenylacetyl chloride, where aqueous tetrahydrofuran, aqueous acetone, aqueous dioxane, etc. are used as a solvent, and sodium hydrogen carbonate, potassium carbonate, triethylamine, etc. are used as a base, and the reaction is carried out at a temperature from 100 to 350C. The optically selective deacylation step by acylase IId lie and IIh IIe can be carried out with a microorganism, cultured product of the microorganism and ortheenzyme produced by the microorganism, which can optically selectively deacylate Compound IId or IIh , thereby producing the optically active Compound IIe . The step can be carried out according to the processes disclosed, for example, in EP 0027882Al, EP 0025602Al, etc. The present B lactam compounds I have strong antimicrobial activities against a wide range of Gram positive and Gram negative bacteria and are useful for curing various infections, as a bactericide or as a component of a disinfectant. Thus, the invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a 6 lactam Compound I or a pharmaceutically acceptable salt thereof in association with a pharmaceutical carrier or diluent. The compounds of this invention are administered by parenteral intramuscular, intraperitoneal, intravenous or subcutaneous injection routes , oral or rectal route of administration and can be formulated in dosage forms appropriate for each route of administration. Preparations according to this invention for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions or emulsions. Examples of non aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying and dispersing agents. They may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use. Compositions for oral administration may be presented in a form suitable for absorption by the gastrointestinal tract. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone fillers, for example, lactose, sugar, maizestarch, calcium phosphate, sorbitol or glycine lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica disintegrants, for example, potato starch or acceptable wetting agent such as sodium lauryl sulphate.The tablets may be coated according to methods well known in the arts. Oral liquid preparations may be in the form of aqueous or oily suspension, solution, emulsions, syrups, etc., or may be presented as a dry product, for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additive such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose sugar syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, emulsifying agents, for example, lecithin or sorbitan monooleate non aqueous vehicles, which may include edible oils, for example, almond oil, coconut oil, propylene glycol or ethyl alcohol preservatives, for example, methyl or propyl p hydroxybenzoates or sorbic acid. Compositions for rectal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax. The dosage of active ingredient in the compositions of this invention may be varied however, it is necessary that the amount of the active ingredient shall be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 5 and 350 mg kg of body weight daily are administered to mammalian patients to achieve an antibiotic effect. Examples of the present invention are given below Example 1 Preparation of l cis 7ss 2 2 amino 4 thiazolyl 2 syn methyoxyimino acetamido 4ss 1 methyl 1,2,3,4 tetrazol 5 yl thio l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI21.1 At first, 112 mg of 2 2 tritylrnino 4 thiazoly1 2 syn methoxyiminoacetic acid is dissolved in 3 ml of anhydrous tetrahydrofuran, and 36 Pl of triethylamine is added thereto under ice cooling. Then, 53 mg of phosphorus pentachloride is added thereto, and the mixture is stirred at the same temperature for one hour to obtain an acid chloride solution. On the other hand, 50 mg of cis 7ss amino 45 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid trifluoroacetate obtained according to the process of Example 33, which is hereinafter referred to as Compound a , is dissolved in a mixture of 4 ml of water and 2 ml of tetrahydrourban, and while triethylamine is added thereto under ice cooling and with stirring to keep the solution at a pH of 7.5 to 8.0, the said acid chloride solution is added dropwise thereto. Then, the mixture is subjected to reaction at the same temperature for two hours. Then, the mixture is adjusted to pH 2 with 1N hydrochloric acid, and a saturated aqueous sodium chloride solution is added thereto.The mixture is extracted three times with ethyl acetate.The organic layer is washed once with a saturated aqueous sodium chloride solution, and the solvent is distilled off under reduced pressure. Then, 8 ml of an aqueous 50 acetic acid solution is added to the residue, and the mixture is stirred at 500C for one hour and then cooled to room temperature. The deposited white precipitate is removed by filtration. The reaction solution is concentrated, and the residue is dissolved in a small amount of dimethyl sulfoxide. The solution is subjected to adsorption on 20 ml of Diaion HP 20 AG resin made by Mitsubishi Kasei KogyoCo., Ltd., Japan in a column. Fractions containing the desired compound, which are eluted with water methanol 2 3 , are concentrated under reduced pressure to obtain 11 mg of the desired compound as powder.Yield 18.8 NMR d6DMSO CD3OD 1.76 2.71 2H, m , 3.90 3H, s , 4.00 3H, s , 5.53 1H, d, J 5.4Hz , 6.37 1H, d, J 2.4Hz , 6.84 1H, s 1 IR maxcm KBr 1790 sh , 1780 sh , 1775, 1770 sh , 1665, 1630 Example 2 Preparation of cis 7ss 2 2 amino 4 thiazolyl 2 syn methoxyimino acetamido 4 alpha 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI22.1 The same procedure as in Example 1 is repeated using 50 mg of cis 78 amino 4ss 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process ofExample 36 in place of Compound a, whereby 19.3 mg of the desired compound is obtained as power. Yield 23.9 . NMR CD3OD 1.92 2.72 2H, m , 3.97 3H, s , 3.99 3H, s , 5.66 1H, d, J 5.4Hz , 6.49 1H, d, J 5.6Hz , 6.84 1H, s 1 IR vmax KBr 1790 sh , 1780 sh , 1775, 1620 1680 Example 3 Preparation of cis 7B 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4 azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI23.1 The same procedure as in Example 1 is repeated using 150 mg of cis 7ss amino 4ss azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid trifluoroacetic acid obtained according to the process of Example 39 in place of Compound a.Purification is carried out with 40 ml of Diaion HP 10 resin made by Mitsubishi Kasei KogyoCo., Ltd., Japan , and fractions containing the desired compound, which are eluted with water methanol 1 1 are concentrated under reduced pressure, whereby 116 mg of the desired compound is obtained as powder. Yield 64.1 . NMR d6DMSO D2O 1.5 2.4 2H, m , 3.91 3H, s , 4.06 1H, m , 4.45 1H, m , 5.41 1H, d, J 5.4.Hz , 6.16 1H, d, J 2.0Hz , 6.83 1H, s 1 IR maxcm KBr 2100, 1785 sh , 1775, 1765 sh 1620 1680 Example 4 Preparation of sodium t cis 7 s 2 2 amino 4 thiazolyl 2 syn 2 carboxypropyl 2 oxyimino acetamido 4 ss azido l azabicyclo 4t2to oct 2 en 8 oxo 2 carboxylate EMI24.1 At first, 167 mg of 2 2 tritylamino 4 thiazolyl 2 syn 2 tert butoxycarbonylpropyl 2 oxy nino acetic acid is added to 4 ml of an anhydrous methylene chloride solution containing 100 mg of phosphorus pentachloride under ice cooling. The mixture is stirred at the same temperature for 30 minutes. Then, 13 p1 of triethylamine is added thereto, and the mixture is then further stirred for 5 minutes.The reaction mixture is concentrated under reduced pressure, and 4 ml of anhydrous tetrahydrofuran is added to the residue to obtain an acid chloride solution. On the other hand, 98 mg of i cis 7 amino 4 azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid trifluoroacetate obtained according to the process ofExample 39, is dissolved in a mixture of 5 ml of water and 5 ml of tetrahydrofuran, and while triethylamine is added thereto under ice cooling and with stirring to keep the solution at a pH of 7.5 to 8.0, the said acid chloride solution is added dropwise thereto. Then, the mixture is subjected to reaction at room temperature for one hour. Then, the mixture is adjusted to pH 2 with 1N hydrochloric acid, a saturated aqueous sodium chloride solution is added thereto, and the mixture is extracted three times with ethyl acetate. The organic layer is washed once with a saturated aqueous sodium chloride solution, and the solvent is distilled off under reduced pressure.Then, 4 ml of anhydrous methylene chloride and 4 ml of trifluoroacetic acid are added.to the residue, and the mixture is stirred at room temperature for 30 minutes. The reaction mixture is subjected to distillation under reduced pressure, and 5 ml of ethyl acetate is added to the residue. The mixture is again concentrated. This procedure is repeated twice. Then, 10 ml of an aqueous 50 acetic acid solution is added to the residue, and the mixture is stirred at 500C for one hour.Then, the reaction mixture is concentrated under reduced pressure, and the residue is dissolved in a small amount of diitiethylsulfoxide. The solution is subjected to adsorption on 20 ml of Diaion HP 20 AG resin in a column, and fractions containing the desired compound, which are eluted with water methanol 1 1 , are concentrated under reduced pressure, whereby 32 mg of the desired compound is obtained as powder. Yield 21.0 . NMR D2O 6 1.57 6H, s , l.57 2.66 2H, m , 4.15 4.79 2H, m , 5.50 1H, d, J 5.lHz , 6.06 1H, d, J 2.0Hz , 7.03 1H, s 1 IR maxcm KBr 2100, 1770 sh , 1765, 1760 sh , 1600 1680Example 5 Preparation of 4R, 6R, 7S 7 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido1 4 azido l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI25.1 The same procedure as in Example 1 is repeated using 15 mg of 4R,6R,7S 7 amino 4 azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 41 in place of Compound a.Purification is carried out with 15 ml of Diaion HP 20AG resin, and fractions containing the desired compound, which are eluted with water methanol 4 3 , are concentrated under reduced pressure, whereby 13 mg of the desired compound is obtained as powder. Yield 47.6 . 22 76.2 c 0.17 50 aqueous methanol D IR and NMR spectra are the same as those of the dl compound Example 3 .Example 6 Preparation of 4R,6R,7S 7 2 2 amino 4thiazolyl 2 syn 3,4 diacetoxy benzoyloxyimino acetamido 4 azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI26.1 The same procedure as in Example 12 is repeated using 112 mg of 4R,6R,7S 7 amino 4 azido l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 41 in place of Compound a, whereby 70 mg of the desired compound is obtained as powder. Yield 22.8 . NMR d6DMSO CD3OD 2.32 6H, s , 5.68 1H, d, J 5.9Hz , 6.13 1H, d, J 2.0Hz , 7.24 lH, s , 7.43 8.05 3H, m IR maxcm 1 KBr 2110, 1790 sh , 1780, 1760, 1750 sh Example 7 Preparation of cis 7B 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4ss amido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride EMI27.1 At first, 16 ml of aqueous 50 methanol, 0.6 ml of 1N hydrochloric acid and 56 mg of 5 palladium carbon catalyst are added to 113 mg of cis 7ss 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4ss azido 1 azabi cyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 3, and hydrogen is passed through the mixture at room temperature with stirring over 5 hours. The catalyst is removed by filtration, and the reaction mixture is concentrated to about 0.5 ml under reduced pressure and then purified with 15 ml of DiaionHP 20 AG resin. Fractions containing the desired compound, which are eluted with water, are concentrated under reduced pressure, whereby 68 mg of the desired compound is obtained as powder. Yield S83 . NMR d6DMSO D20 6 1.4 2.4 2H, m , 3.91 3H, s , 4.03 2H, m , 5.39 1H, d, j 5.4Hz , 5.69 1H, d, J 1.5Hz , 6.83 1H, s IR cm1 max KBr 1755, 1750 sh , 1620 1670 Example 8 Preparation of cis 7ss 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4ss acetamino 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI28.1 At first, 25 mg of cis 7B 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4ss amino 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride is dissolved in 2 ml of anhydrous pyridine.Then, 30 1 of acetic anhydride is added thereto under ice cooling and with stirring, and the mixture is stirred at the same temperature for one hour. Ice is added to the reaction mixture, and the resulting mixture is stirred for 10 minutes and concentrated. The residue is dissolved in a small amount of dimethylsulfoxide, and the solution is purified with 10 ml of Diaion HP 20 AG resin. Fractions containing the desired compound, which are eluted with water methanol 4 1 , are concentrated under reduced pressure to obtain 14 mg Of the desired compound as powder. Yield 55.2 . NMR CD3Od D2O 1.32 2 42 2H, m , 2.02 3H, s , 3.97 3H, s , 4.21 1H, m , 5.45 1H, d, J 5.2Hz , 6.04 1H, d, J 2.4Hz , 6.91 1H, s IR maxcm 1 KBr 1780 sh , 1770, 1760 sh , 1620 1680Example 9 Preparation of t cis 7B 12 2 imino 4 thiazolyl 2 syn methOxyiminoacetamido 4ss N methylureido l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI28.2 At first, 45 mg of cis 7S 2 2 amino 4 thiazolyl 2 syn methoxyimioacetamido 4ss amino 1azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride, obtained according to the process of ReferenceExample 7 is dissolved in 3 ml of anhydrous dimethylformamide.Then, 70 ul of triethylamine is added thereto under ice cooling and with stirring, thereafter 9 1 of methyl isocyanate is added thereto, and the mixture is subjected to reaction at the same temperature for 45 minutes.Then, 3 ml of water is added to the reaction mixture, and the mixture is adjusted to pH 3.0 with 1N hydrochloric acid.The reaction mixture is concentrated to 0.5 ml under reduced pressure, and a small amount of water is added thereto to obtain a homogenous solution. The solution is subjected to purification with 20 ml of Diaion HP 20 AG resin. Fractions containing the desired compound, which are eluted with water methanol 4 1 , are concentrated under reduced pressure to obtain 40 mg of desired compound as powder.Yield 84.7 . NMR d6DMSO D2O 2,63 3H, s , 3.90 3H, s , 4.57 1H, m , 5.42 1H, d, J 5.2Hz , 6.12 1H, d, J 2.0Hz , 6.83 1H, s IR ,cm1 1 1775, 1765, 1755, 1620 1680 Example 10 Preparation of cis 7ss 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4ss ureido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI29.1 At first, 1.5 ml of dimethylformamide, 0.2 ml of acetic acid and 3 ml of water are added to 12 mg of cis 7ss 2 2 amino 4 thiazolyl 2 syn methoxyimino acetamido 4ss amino 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride obtained according to the process of Example 7, and then 20 mg of sodium cyanate is added to the mixture.The resulting mixture is stirred at room temperature for 2 hours. The reaction mixture is concentrated under reduced pressure, and purified with 10 ml of Diaion HP 20 AG resin.Fractions containing the desired compound, which are eluted with water methanol 8 1 , are concentrated under reduced pressure to obtain 10 mg of the desired compound as powder.Yield 82.0 . NMR CD3OD D2O 3.97 3H, s , 5.43 1H, d, J 5.1Hz , 6.05 1H, brs , 6.85 lH,s IR cm1 max K3r 1770 sh , 1765, 1760 sh , 1630 1680 Example 11 Preparation fo 4S,6R,7S 7 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamidol 4 methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI30.1 The same procedure as in Example 1 is repeated using 43.3 mg of 4S,6R,7S 7 amino 4 methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 46, and purification is carried out with 10 ml of Diaion HP 20 AG resin. Fractions containing the desired compound eluted by water methanol 3 2 are concentrated under reduced pressure to obtain 36 mg of the desired compound as powder.Yield 44,7 . NMR CD3OC D2O 6 1.53 2.43 2H, m , 3.45 3H, s , 3.98 3H, s , 3.8 4.2 2H, m , 5.58 1H, d, J 5.4Hz , 6.46 1H, d, J 5.0Hz , 6.87 1H, s IR maxcm 1 KBr 1770, 1760 sh , 1670, 1630 alpha D20 57.2 c 0.5, methanol Example 12 Preparation of diphenylmethyl ester of 4R,6R,7S 7 2 2 trytylamino 4 thiazolyl 2 syn methoxyiminoacetamido 1 phenyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,22,0 oct 2 en 8 oxo 2 carboxylic acid EMI31.1 At first, 500 mg of diphenylmethyl ester of 4st6Rt7S3 7 2 2 tritylamino 4 thiazolyl 2 syn meth iminoacetamido 4 hydroxy 1 azabicyclo 4,2,0 oct 2 en 8oxo 2 carboxylic acid hereinafter referred to as Compound b obtained according to the process of Reference Example 1, is dissolved in 5.7 ml of anhydrous dimethylformamide.Then, 333 mg of triphenylphosphine is added thereto under ice cooling and with stirring, and then 226 mg of Nbromosuccinimide is added thereto in 5 portions over 15 minutes. The mixture is stirred at the same temperature for one hour. On the other hand, 169 mg of 1 phenyl 1,2,3,4tetrazol 5 thiol is dissolved in 1.5 ml of dimethylformamide, and 45 mg of 50 sodium hydride is added thereto under ice cooling. The mixture is stirred as such at room temperature for 30 minutes. The resulting solution is added to the said reaction mixture, and then the mixture is stirred under ice cooling for one hour. Then, 0.5N hydrochlonic acid is added to the reaction mixture, and the.mixture is extracted twice with ethyl acetate. The extract is washed three times with water and once with a saturated sodium chloride solution, and dried over sodium sulfate.The solvent is distilled off under reduced pressure, and the oily residue is subjected to purification by silica gel chromatography 50 g, n hexane ethyl acetate 1 1 , whereby 470 mg of the desired compound is obtained as powder.Yield 78.5 . NMR CD30D CDC13 6 3.90 3H, s , 5.50 1H, d, J 5.OHz , 6.50 lH, d, J 2.0Hz , 6.67 1H, s , 6.93 1H, s , 7.27 7.63 3OH, m IR maxcm 1 CHCl3 1790, 1740, 1690Example 13 Preparation of 4R,6R,7S 7 2 2 amino 4thiazolyl 2 syn methoxyiminoacetamido 4 phenyl 1,2,3,4tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2carboxylic acid EMI33.1 At first, 470 mg of diphenylmethyl ester of 4R,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido 4 1 phelyl 1,2,3,4 tetrazol 5 yl thio 1azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hereinafter referred to as Compound c obtained according to the process of Example 12, is dissolved in 30 ml of anhydrous methylene chloride, and 7.5 ml of trifluoroacetic acid is added thereto under ice cooling. The mixture is allowed to stand at the same temperature for 30 minutes. The reaction mixture is concentrated under reduced pressure, and ethyl acetate is added to the residue, and the mixture is again concentrated under reduced pressure.This operation is repeated three times. Then, 20 ml of aqueous 50 acetic acid is added to the residue, and the mixture is stirred at 550C for 45 minutes. The reaction mixture is concentrated under reduced pressure, the residue is dissolved in a small amount of dimethylsulfoxide, and the solution is subjected to adsorption on 60 ml of Diaion HP 10 resin in a column. Fractions containing the desired compound, which are eluted with water methanol 1 2 , are concentrated under reduced pressure. The resulting powder is disintegrated in a solution consisting of 25 ml of ethyl acetate and 75 ml of n hexane, and the desired compound is separated by filtration, whereby 102 mg of the powder is obtained. Yield 39.4 . NMR d6DMSO 1.51 2.47 2H, m , 3.75 3H, s , 4.07 1H, m , 4.84 1H, m , 5.52t1H, dd, J 5.4Hz, 8.8Hz , 6.31 1H, d, J 2.0Hz , 6.76 1H, s , 7.17 2H, brs , 7.66 5H, s , 9.26 1H, d, J 8.8Hz IR maxcm 1 KBr 1790 sh , 1775, 1770 sh , 1660, 1630Example 14 Preparation of diphenylmethyl ester of 4R,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido 4 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en oxo 2 carboxylic acid EMI34.1 The same procedure as in Example 12 is repeated using 1.19 g of diphenylmethyl ester of 4S,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido 4hydroxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Reference Example 1 in place of compound 6 and 348 mg of 1 methyl l,2,3,4 tetrazol 5 thiol, whereby 722 mg of the desired compound is obtained as powder. Yield 58.0 . NMR CDCl3 CD3OD 3,90 3H, s , 3.97 3H, s , 4.67 1H, m , 5.50 1H, d, J 5.5Hz , 6.43 1H, d, J 2.0Hz , 6.67 lH, s , 6,93 1H, s , 7.33 25H, m IR cm1 max CHC13 1795, 1790 sh , 1740, 1695, 1690 Example 15 Preparation fo 4R,6R,7S 7 2 2 amino 4thiazolyl 2 syn methoxyiminoacetamido 4 1 methyl 1,2,3,4tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2carboxylic acid EMI35.1 The same procedure as in Example 13 is repeated using 722 mg of diphenylmethyl ester of 4R,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido 4 l methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 15 in place of Compound c.Purification is carried out with 120 ml of Diaion HP 10 resin, and fractions containing the desired compound, which are eluted with water methanol 1 1 , are concentrated under reduced pressure to obtain 176 mg of the desired compound as powder.Yield 42.2 . NMR and IR data are identical with those of the corresponding dl isomer Example 1 . Example 16 Preparation of diphenylmethyl ester of 4R,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminOacetamido 4 azido l azabicyclot4,.2ff0 oct 2 en 8 oxo 2 carboxylic acid EMI35.2 The same procedure as in Example 12 is repeated using 198 mg of diphenylmethyl ester of 4S,6R,7S 7 2 2tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido 4 hydroxy l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Reference Example 1 in place of Compound b and 65 mg of sodium azide. Purification is carried out according to silica gel chromatography 20 g, n hexane ethyl acetate 2 1 , whereby 119 mg of the desired compound is obtained as powder. Yield 58.2 . NMR CDCl3 CD3OD 1.50 2.57 2H, m , 4.00 3H, s , 5.42 1H, d, J 5.5Hz , 6.32 1H, d, J 2.0Hz , 6.63 1H, s , 6.93 1H, s , 7.33 25H, m IR maxcm 1 CHCL3 2100, 1795, 1785, 1740, 1690 sh 1685 Example 17 Preparation of 4R,6R,7S 7 t2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamaido 4 azido 1 azabicyclo 4,2,0 oct2 en 8 oxo 2 carboxylic acid EMI36.1 The same procedure as in Example 13 is repeated using 119 mg of diphenylmethyl ester of 4R,6R,7S 6 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminOacetamidou 4 azido 1 azabicyclol4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Example 16 in place of Compound c.Purification is carried out with 20 ml ofHP 10 resin, and fractions containing the desired compound, which are eluted with water methanol 4 3 , are concentrated under reduced pressure, whereby 26 mg of the desired compound is obtained as powder. Yield 43.9 . NMR and IR data are identical with those of the corresponding dl isomer Example 3 . Exemple 18 Preparation of 4R,6R,7S 7 2 2 amino 4thiazolyl 2 syn methoxyiminoacetamido 4 1 carboxymethyl 1,2,3, 4 tetrazol 5 yl thio 1 azabicyclo 4 ,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI37.1 The same procedure as in Example 12 is repeated using 396 mg of diphenylmethyl ester of 4S,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminoacetamido3 4 hydroxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Reference Example 1 in place of Compound b and 160 mg of 1 carboxymethyl 1,2,3,4 tetrazole 5 thiol. However, the reaction product is subjected to removal of protective group without silica gel chromatographic purification, and then treated in the same manner as in Example 13.Purification is carried out with 60 ml of Diaion HP 10 resin, and fractions containing the desired compound, which are eluted with water methanol 3 1 , are concentrated under reduced pressure to obtain 80 mg of the desired compound as powder. NMR CD3OD D2O d6DMSO 6 3.89 3H, s , 5.26 2H, s , 5.51 1H, d, J 4.9Hz , 6.36 1H, d, J 2.5Hz , 6.84 1H, s IR cm1 IR vmax KBr 1785, 1780 sh , 1605 1695 Example 19 Preparation of sodium 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyiminoacetamido 4 5 methyl1,3,4 thiadiazol 2 yl thio 1 azabicyclo 4,2,0 oct 2 en8 oxo 2 carboxylate EMI38.1 At first, 176 mg 0.416 m moles of t4S,6R,7S 7 t2 2 aminothiazol 4 yl 2 syn methoxyiminoacetamido 4 acetoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid obtained according to the process of Reference Example 4 hereinafter referred to as Compound e is suspended in 8 ml of water, and the suspension is adjusted to pH 7.5 with a saturated sodium hydrogen carbonate solution and then admixed with water to make 10 ml of a solution. Then, 66 mg 0.499 m moles of 5 methyl 2 mercapto 1,3,4 thiadiazole is added thereto and the mixture is stirred at 500C for 2.5 hours.The mixture is allowed to stand at room temperature for 15 hours, and the reaction mixture is adjusted to pH 6.9 with dilute hydrochloric acid and concentrated under reduced pressure to about 5 ml. The concentrate is purified with 100 ml of Diaion HP 10 resin in a column. After washing with 200 ml of water and 200 ml of water methanol 5 1 , fractions eluted with water methanol 1 2 are joined together, and concentrated under reduced pressure to obtain 71.6 mg 0.138 m moles of the desired compound as yellow powder. Yield 33.28. NMR D2O CD 6.91 1H, s , 6.20 1H, d, J 5.4Hz , 5.62 1H, d, J 5.4Hz , 3.95 3H, s , 2.76 3H, s , 2.6 1.9 2H, m IR max KBr 3400, 1775 s , 17 , 1680 s , 1 Example 20 Preparation of sod m 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyimino acetanido 4 2 amino 1,3,4thiadiazol 5 yl thio 1 azabicyclo 4,2,0, oct 2 en 8 oxo 2 carboxy late EMI39.1 In this example, reaction of 176 mg 0.416 m moles of Compound e with 66.5 mg 0.499 m moles of 2 amino 5mercapto 1,3,4 thiadiazole and purification are carried out in the same manner as in Example 19, and fractions eluted with water methanol 5 1 are joined together and concentrated under reduced pressure to obtain 106.5 mg 0.205 m moles of the desired compound as yellow powder. Yield 41.1 . NMR D2O CD3OD 6 6.88 1H, s , 6.15 1H, d, J S.4Hz , 5.62 lH d, J 4.9Hz , 4.6 3.9 2H, m , 3.94 3H, s , 2.4 1.8 2H, m IR cm1 max KBr 3300, 1780 s , 1760, 1680 s , 1670 Example 21 Preparation of sodium 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyiminoacetamido 4 benzOthiazol 2 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate EMI39.2 In this example, reaction of 134 mg 0.315 m moles of Compound e with 105 mg 0.63 m moles of 2 mercaptobenzothiazole and purification are carried out in the same manner as in Example 19, and fractions eluted with watermethanol 1 1 and 1 3 are joined together and concentrated under reduced pressure to obtain 55.1 mg of yellow powder.The powder is purified with 10 ml of Diaion CHP 20P.After washing with 10 ml of water, 20 ml of water methanol 8 1 , 20 ml of water methanol 5 1 and 10 ml of watermethanol 3 1 , fractions eluted with water methanol 1 1 are joined together and concentrated under reduced pressure to obtain 20.7 mg 0.0375 m moles of the desired compound as yellow powder. Yield 11.9 . NMR D2O CD3OD DMSO d6 6 8.1 7.8 2H, m , 7.7 7.3 2H, m , 6.82 1H, s , 6.13 1H, d, J 5.4Hz , 5.60 1H, d, J 4.9Hz , 5.1 4.9 1H, m , 4.3 4.0 1H, m , 3.88 3H, s , 2.5 1.8 2H, m IR max KBr 3400, 1780 s , 1765, 1680, 1660 Example 22 Preparation of sodium 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyimino acetamido 4 pyridin 2yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate EMI40.1 At first, 400 mg 0.945 m moles of Compound e is reacted with 177 mg 1.59 m moles of 2 mercaptopyridine in the same manner as in Example 19.The reaction mixture is purified with 180 ml of Diaion HP 10. After washing with 400 ml of water, 400 ml of water methanol 6 1 , 300 ml of water methanol 3 1 and 100 ml of water methanol 1 1 , fractions eluted with water methanol 1 1 and 1 3 are joined together and concentrated under reduced pressure.The solid matters are dissolved in 5 ml of methanol, and 50 ml of ether is added thereto. The resulting precipitate is separated by centrifugation and dried to obtain 70.6 mg 0.142 m moles of the desired compound as yellow powder.Yield 15.0 . NMR DMSO d6 9.28 1H, d, J 8.8Hz , 8.46 1H, d, J 4.4Hz , 7.76 7.21 2H, m , 6.73 1H, s , 5.97 1H, d, J 5.4Hz , 5.48 1H, dd, J 8.8, 5.4Hz , 4.35 1H, m , 3.77 3H, s , 2.1 1,9 2H, m 1 IR cmmax KBr 3400, 1775, 1765, 1685 1675, 1635Example 23 Preparation of sodium 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyimino acetamido 4 pyridin 4 yl thio l azabicyclot4,2,0 oct 2 en 8 oxo 2 carboxylate EMI41.1 At first, 400 mg 0.945 m moles of Compound e is reacted with 158 mg 1.42 m moles of 4 mercaptopyrioine in the same manner as in Example 19. The reaction mixture is washed three times with 10 ml of ethyl acetate, and adjusted to pH 6 with 6N hydrochloric acid. The mixture is concentratea unaer reduced pressure to about 5 ml, adjusted to pH 3 with 2N hydrochloric acid and purified with 200 ml of Diaion HP 10 resin.After washing with 500 ml of water, 550 ml of water methanol 10 1 , 600 ml of watermethanol 5 1 , and 450 ml of water methanol 2 1 fractions eluted with water methanol 1 2 are joined together and concentrated under reduced pressure to obtain 250 mg of yellow powder. The powder is dissolved in an aqueous sodium hydrogen carbonate solution, and the solution is purified with 50 ml of Diaion HP 10 resin. After washing with 200 ml of water and 150 ml of water methanol 5 1 , fractions eluted with water methanol 5 1 and 4 1 are joined together and concentrated under reduced pressure to obtain 105 mg of yellow powder.The same purification is repeated, and fractions containing the desired compound are joined together and concentrated under reduced pressure to obtain 78.2 mg 0.157 m moles of yellow powder.Yield 16.6 . NMR D2O 8.40 8.23 2H, m , 7.44 7.31 2H, m , 6.88 1H, s , 6.17 1H, d, J 5.4Hz , 5.59 1H, d, J 5.1Hz , 4.7 4.6 1H, m , 4.3 4.1 1H, m , 3.91 3H, s , 2.2 1,9 2H, m cm 1 IR maxcm KBr 3300, 1780 s , 1760, 1680, 1670Example 24 Preparation of sodium 4S,6R,7S 7 2 2 amino thiazol 4 yl 2 syn methoxyimino acetamido 4 lH 1,2,4 triazol 3 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate EMI42.1 At first, 400 mg 0.945 m moles of Compound e is reacted with 143 mg 1.42 m moles of 1H 1,2,4 triazole 3 thiol at 500C for 5 hours in the same manner as in Example 19.After cooling, the reaction mixture is purified with 200 ml of Diaion HP 10 resin. After washing with 500 ml of water, fractions eluted with water methanol 8 1 and 5 1 are joined together, and concentrated under reduced pressure to obtain 219 mg of yellow powder. The powder is dissolved in an aqueous sodium hydrogen carbonate, and the solution is repurified with 50 ml of Diaio HP 10 resin.After washing with 100 ml of water, fractions eluted with water methanol 10 1 are joined together. and concentrated under reduced pressure to obtain 132 mg 0.271 m moles of the desired compound as yellow powder. Yield 28.7 . NMR D2O CD3OD 6 8.41 1H, s , 6.86 1H, s , 6.11 1H, d, J 4.9Hz , 5.55 lH, d, J 5.4Hz , 4.6 4.4 1H, m , 4.3 4.0 1H, m , 3.86 3H, s , 2.3 1.9 2H, m IR maxcm 1 KBr 330, 1760, 1675, 1600Example 25 Preparation of 4S,6R,7S 7 2 2 amino 4 thiazolyl 2 syn methoxyiminoacetamido 4 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI43.1 At first, 450 mg of Compound e is reacted with 248 mg of 1 methyl 1,2,3,4 tetrazole 5 thiol in the same manner as in Example 19. The reaction mixture is adjusted to p11 2.5 with 0.5N hydrochloric acid, and concentrated under reduced pressure. The residue is dissolved in dimethylsulfoxide, and the solution is purified with 120 ml ofDiaion HP 10 resin. Fractions eluted with water methanol 4 3 are joined together,.. and concentrated under reduced pressure to obtain 116 mg of the desired compound as powder.Yield 22.8 . NMR and IR data are identical with those of the corresponding dl isomer Example 2 .Example 26 Preparation of 4S,6R,7S 7 2 2 amino 4 thiazolyl 2 syn methOxyiminoacetamido 4 azido 1 azabicyclot4,2,01oct 2 en 8 oxo 2 carboxylic acid EMI44.1 At first, 150 mg of Compound e is reacted with 46 mg of sodium azide in the same manner as in Example 19.The reaction mixture is adjusted to pH 2.5 with 0.5N hydrochloric acid, and concentrated under reduced pressure.The residue is dissolved in a small amount of dimethylsulfoxide, and the solution is purified with 20 ml of Diaion HP 10 resin. Fractions eluted with water methanol 4 3 are joined together and concentrated under reduced pressure to obtain 44 mg of the desired compound as powder.Yield 30.6 . NMR CD3OD 1.5 2.4 2H, m , 3.97 3H, s , 4.47 1H, m , 5.60 1H, d, J 5.4Hz , 6.43 1H, d, J 5.4Hz , 6.83 1H, s IR max KBr 2120, 1785 sh , 1775, 1620 1665 Example 27 Preparation of 4,6R,7S 7 2 2 aminothiazol 4yl 2 syn methoxyimino acetamido 4 pyridin 1 yl 1azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI44.2 At first, 400 mg 0.944 m moles of Compound e and 1.98 g 13.2 m moles of sodium iodide are suspended in 0.5 ml of water and the suspension is heated at 800C. Then, 0.54 ml 6.72 m moles of pyridine is added thereto, and the mixture is heared at 800C with stirring for 50 minutes. After cooling to room temperature, the mixture is diluted with 100 ml of water, and concentrated under reduced pressure to about 50 ml to distill off pyridine.Then, 50 ml of water is added to the concentrate, and two drops of methyl isobutyl ketone are added thereto. The mixture is adjusted to pH 1.0 with 2N hydrochloric acid, washed twice with 40 ml of ethyl acetate, adjusted to pH 6.0 with an aqueous 1N sodium hydroxide solution and then concentrated under reduced pressure. The residue is purified with 130 ml of ion exchange resin Amberlite XAD 2 made by Rohm and Haas Co. . After washing with 200 ml of water, elution is carried out with 10 aqueous ethanol.Fractions containing the desired compound are joined together, and concentrated under reduced pressure to obtain 187 mg 0.40 m moles of the desired compound as yellow powder.Yield 42.5 . NMR D2O 6 9.1 7.9 5H, m , 6.94 1H, s , 6.14 1H, d, J 5.4Hz , 5.9 5.8 1H, m , 5.62 1H, d, J 5.1Hz , 4.01 3H, s , 4.1 3.9 1H, m , 2.6 2.3 2H, m 1 IR vcmax KBr 3400, 1775 s , 1765, 1750, 1665, 1630, 1624, 1540Example 28 Synthesis of sodium salt of 4R,6R,7S 7 2 2aminothiazol 4 yl 2 syn 1 3,4 dihydroxybenzoyl 1 methyl1 ethyl oxyiminoacetamido 4 azido 1 azabicyclo 4,2,0 oct2 en 8 oxo 2 carboxylic acid EMI45.1 At first, 706 mg of 2 2 tritylaminothiazol 4 yl 2 Syn 1 3t4 diacetOXybenZOyl l methyl l ethyl oxyiminoacetic acid is dissolved in 9.3 ml of anhydrous tetrahydrofuran, and 143 p1 of triethylamine is added thereto. The mixture is cooled to 150C with stirring.Then, 213 mg of phosphorus pentachloride is added thereto, and the mixture is stirred for 30 minutes. On the other hand, 207 mg of 4R,6R,7S 7 amino 4 azido l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is suspended in 9.3 ml of water and 9.3 ml of tetrahydrofuran, and the mixture is adjusted to pH 7.5 with triethylamine. Then, the said acid chloride solution is added dropwise to the mixture under ice cooling over 15 minutes, while keeping the mixture at pH 7 7.5 with triethylamine.Then, the mixture is stirred under ice cooling for 45 minutes. Then, 1N hydrochloric acid is added to the reaction mixture to make pH 1.5. Then, 50 ml of water is added thereto, and the mixture is extracted twice with 100 ml of ethyl acetate. The ethyl acetate layer is washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate and concentrated under reduced pressure to obtain 830 mg of yellow solid. Then, 20 ml of acetic acid is added to the yellow solid, and also 20 ml of water is added dropwise thereto with heating to 50 550C and stirring.Then, the mixture is stirred at the same temperature for 30 minutes, and then the reaction mixture is cooled. The precipitated crystals are removed by filtration, and the filtrate is concentrated under reduced pressure. The residue is dissolved in 40 ml of methanol and 20 ml of water, and a saturated aqueous sodium hydrogen carbonate solution is added thereto. The mixture is stirred at room temperature for 4 hours while keeping the mixture at pH 7.0.Then, the reaction mixture is adjusted to pH 7.0 with 1N hydrochloric acid, and concentrated to about 10 ml under reduced pressure. The solution as such and the resulting solid matters, after dissolution in 2 ml of dimethylsulfoxide, are both adsorbed on 180 ml of Diaion HP 10 in a column, and the column is washed with 600 ml of water and then with 400 ml of water methanol 10 1 . Fractions containing the desired compound eluted with water methanol 3 2 are collected and concentrated under reduced pressure to obtain 145 mg of the desired compound as pale brown solid matters.Yield 26.4 . IR V cm1 max KBr 2120, 1780 sh , 1775 sh , 1770, 1760 sh , 1670, 1600 NMR D2O 7.50 7.73 2H, m , 6.68 7.00 1H, nm . 6.72 1H, s , 5.94 1H, d, J 1.7Hz , 5.39 1H, d, J 4.9Hz , 3.94 4.54 2H, m , 1.46 2.46 2H, m , 1.58 brs, 6H Example 29 Synthesis of sodium salt of 4S,6R,7S 7 2 2aminothiazol 4 yl 2 3,4 dihydroxybenzymido acetamido4 pyridin 4 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI47.1 At first, 600 mg 1 m mole of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2 3, 4 diacetoxybenzamido acetamido4 acetoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid, 167 mg 1.5 m moles of 4 mercaptopyridine, and 336 mg 4 m moles of sodium hydrogen carbonate are dissolved in 120 ml of water and the solution is stirred at 500C for 3 hours. The reaction mixture is cooled to room temperature, and then subjected to column chromatography with 220 ml ofDiaion HP 10. After washing with 1,000 ml of water and 500 ml of water methanol 10 1 , the fractions eluted with water methanol 8 1 2 1 are collected and concentrated under reduced pressure to obtain 340 mg of yellow solid matters. The solid matters are dissolved in water, and the solution is subjected to column chromatography with 50 ml of Diaion HP 10. After washing with 200 ml of water and 100 ml of water methanol 8 1 , the fractions eluted with water methanol 2 1 are collected and concentrated under reduced pressure to obtain 180 mg 0.30 in moles of the desired compound as yellow powder. NMR DMSO D2O ppm 8.4 8.25 2H, m , 7.4 7.2 4H, m , 6.95 1H, d, J 8Hz , 6.68 1H, s , 6.15 605 1H, m , 5.53 1H, s , 5.38 1H, d, J 4.6Hz , 4.7 4..3 1H, m , 4.2 3.8 1H, m , 2.2 1.5 2H, m IR KBr maxcm 1 3350, 1760, 1610, 1585 Example 30 Synthesis of sodium salt of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2 3, 4 dihydroxybenzamidoacetamido 4 2 amino 1,3,4 thiadiazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI48.1 By reaction of 600 mg 1 m mole of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2 3,4 diacetoxybenzamidoacetamido4 acetoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid and 200 ing 1.5 m moles of 2 amino 5 mercapto l,3,4 thiadiazole and by successive purification in the same manner as in Example 29, 91 mg 0.145 m moles of the desired compound is obtained as yellow powder. NMR D2O ppm 7.3 7.0 2H, m , 6.9 6.7. 1H, m , 6.63 1H, s , 6.08 1 2H, d, J 5.4Hz , 6.07 1 2Hm d, J 5.4Hz , 5.48 1H, s , 5.34 1H, d, J 4.611z , 4.3 3.7 2H, m , 2.3 1.4 2H, m IR KBr IR KBr maxcm 3300, 1770, 1760, 1640, 1600, 1510 Example 31 Preparation of tertiary butyl ester of cis 7ss phthalimido 4ss 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 an 8 oxo 2 carboxylic acid EMI49.1 At first, 184 ml of anhydrous carbon tetrachloride, 1.78 g of N bromosuccinimide and 0.53 g of aobisisobutyro nitrile are added to 3.68 g of tertiary butyl ester of i cis 4ss phthalimido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2carboxylic acid, and the mixture is refluxed with heating and stirring for 15 minutes. After the solvent is distilled off, 20 ml of anhydrous dimethylformamide is added to the residue.While the resulting solution is cooled to 50C with stirring, the following solution A is added thereto, and the mixture is stirred at room temperature for 45 minutes. preparation of solution A 480 mg of 50 sodium hydride is added to a solution of 1.16 g of 1 methyl 1,2,3,4 tetrazol 5 thiol in 20 ml of anhydrous dimethylformamide at 0 C, and then the mixture is stirred at room temperature for 15 minutes . Then, 1N hydrochloric acid is added to the reaction mixture to adjust pH to about 5, and then dimethylformamide is substantially distilled off. The residue is distributed in water chloroform. The chloroform layer is washed four times with water and once with a saturated aqueous sodium chloride solution, and then dried over sodium sulfate.Then, the solution is concentrated under reduced pressure, and the residue is crystallized from ethyl acetate n hexane, whereby 2.71 g of the desired compound is obtained. Yield 56.2 . NMR CDCl3 1.57 9H, s , 3.93 3H, s , 4.13 1H, m , 4.78 111, m , 5.67 1H, d, J 5.5Hz , 6.25 111, d, J 2.0Hz , 7.30 1Hz,s , 7.83 4H, m , IR cm1 max KBr 1805, 1795, 1785 sh , 1740, 1730 sh , 1630Example 32 Preparation of tertiary butyl ester of cis 76 amino 4 B l methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI50.1 At first, 70 ml of tetrahydrofuran and 13 ml of water are added to 2.71 g of tertiary butyl ester of cis 76 phthalimido dss methyl 1,2,3, tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid.The resulting solution is cooled to 0 C with stirring, and a solution of 1.88 g of sodium sulfide nonhydrate in 18 ml of water is added dropwise thereto over 8 minutes. The mixture is further stirred at the same temperature for 2 minutes, adjusted to about pH 6 with 1N hydrochloric acid, and concentrated under reduced pressure to distill off tetrahydrofuran. The solution is adjusted to p11 2 with 1N hydrochloric acid, and extracted twice with ethyl acetate.The organic layer is washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated under reduced pressure to obtain crude oily matters.The oily matters are dissolved in 16 ml of anhydrous tetrahydrofuran, and 0.79 g of dicyclohexylcarbodiimide is added thereto at room temperature with stirring. The mixture is further stirred as it is for 45 minutes, and deposited urrea is removed by filtration. The filtrate is cooled to 780c, and 190 1 of methylhydrazine is added dropwise thereto with stirring. The mixture is further stirred as it is for 20 minutes. Then, 4 ml of 1N hydrochloric acid is added to the reaction mixture to adjust pH to about 2, and the mixture is heated to room temperature over about 40 minutes. The mixture is further stirred at room temperature for 15 minutes, and concentrated under reduced pressure.Water is added to the residue, and precipitated insoluble matters are removed by filtration. The filtrate is washed twice with ethyl acetate, and the aqueous layer is adjusted to about pH 9 with a saturated aqueous sodium hydrogen carbonate under ice cooling and extracted 7 times with ethyl acetate. The organic layers are joined together, washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated under reduced pressure to obtain 1.15 g of crude oily matters. The oily matters are purified by silica gel chromatography 120 g, ethyl acetate methanol 30 1 , whereby 347 mg of the desired compound is obtained. Yield 17.5 . In addition, 441 mg of tertiary butyl ester of cis 7ss amino 4a 1 methyl 1,2t3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid, which has undergone epimerization at position 4, is also obtained as a low polar compound see Reference Example 7 . NMR CDC13 1.53 9H, s , 3.70 5.07 3H, m , 4.00 3H, s , 6.25 rH, brs 1 Cm Vmax CDCl3 1790 sh , 1785, 1730, 1630 Example 33 Preparation of cis 7B amino 46 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en8 oxo 2 carboxylic acid trifluoroacetate EMI52.1 At first, 133 mg of tertiary butyl ester of cis 7B amino 4ss 1 ne thyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 2 ml of anhydrous methylene chloride, and 2 ml of trifluoroacetic acid is added thereto. The mixture is allowed to stand at room temperature for 90 minutes, and then concentrated under reduced pressure.Ethyl acetate is added to the residue, and the mixture is again concentrated under reduced pressure. This operation is repeated three times. The residue is disintegrated in 3 ml of ether ethyl acetate 3 1 and subjected to filtration, whereby 123 mg of the desired compound is obtained as powder. Yield 79.48. NMR d6DMSO 6 3.99 3H, s , 4.57 2H, m , 6.18 1H, d, J 2.5Hz 1 IR vmax KBr 1810 sh , 1805, 1620, 1550 Examnle 3 Preparation of tertiary butyl ester of cis 7ss phthalimido 4a 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI52.2 At first, 18 ml of anhydrous carbon tetrachloride, 178 mg of N bromosuccinimide and 53 mg of azobisisobutyronitrile are added to 368 mg of tertiary butyl ester of cis 7ss phthalimidoi 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid, and the mixture is refluxed with heating and stirring for 20 minutes.After the solvent is distilled off under reduced pressure, 5 ml of anhydrous methylene chloride is added to the residue, and then 116 mg of 1 methyl 1,2,3,4 tetrazol 5 thiol and 140 mg of zinc chloride are added thereto. The mixture is stirred at room temperature for 3 hours. The solvent is distilled off under reduced pressure, and the residue is purified by silica gel chromatography 30 g, chloroform acetone 30 1 , whereby 156 mg of the desired compound is obtained.Yield 32.3 . NMR CDC13 6 1.57 9H, s , 3.90 3H, s , 4.15 1H, m , 4.83 1H, m , 5.73 1H, d, J 5.7Hz , 6.32 1H, d, J 5.7Hz , 7.25 1H, s , 7.83 4H, m IR cm1 max KBr 1805 sh , 1800, 1790 sh , 1785, 1735, 1730, 1635Example 35 Preparation of tertiary butyl ester of cis 7ss amino 4a 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI53.1 Dephthalylization is carried out in the same manner as in Example 32 with 813 mg of tertiary butyl ester of cis 7ss phthalimido 4 alpha 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oXo 2 carboxylic acid, whereby 193 mg of the desired compound is obtained. Yield 32.4 . The compound can also be prepared by epimeriza tion according to the process of Reference Example 4. NMR CDCl3 1.57 9H, s 3.80 5.07 3H, m , 3.97 3H, s , 6.33 1H, d, J 5.5Hz IR maxcm 1 CDCl3 1790 sh , 1780, 1730, 1630Example 36 Preparation of cis 76 amino 4a 1 methyl l,2,3,4 tetrazol 5 yl thio l azabicyc1o 4,2,0 oct 2 en8 oxo 2 carboxylic acid EMI54.1 At first, 331 mg of tertiary butyl ester of cis 7ss amino 4a 1 methyl 1,2,3,4 tetrazol 5 yl thio 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 4 ml of anhydrous methylene chloride, and 4 ml of trifluoroacetic acid is added thereto.The mixture is allowed to stand at room temperature for 90 minutes, and concentrated under reduced pressure. Ethyl acetate is added to the residue, and the mixture is again concentrated under reduced pressure. This operation is repeated three times. Then, 10 ml of water and 3 ml of methanol are added to the residue, the mixture is adjusted to pH 3.5 with a saturated sodium hydrogen carbonate solution, and the resulting precipitate is separated by filtration. The precipitate is disintegrated in ethyl acetate, whereby 119 mg of the desired compound is obtained as powder. Yield 42.7 . NMR d6DMSO 3.98 3H, s , 4.58 2H, m , 6.31 1H, d, J 5.4Hz IR max KBr 1885 sh , 1800, 1650 Example 37 Preparation of tertiary butyl ester of cis 7ss phthalimido 4ss azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo2 carboxylic acid EMI55.1 Reaction and extraction are carried out in the same manner as in Example 31 with 3.68 g of tertiary butyl ester of cis 7ss phthalimido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid and 780 mg of sodium azide.The organic layer is concentrated under reduced pressure, and the residue is purified by silica gel chromatography 150 g, n hexane ethyl acetate chloroform 3 2 1 , whereby 3.0 g of the desired compound is obtained as powder.Yield 74.0 . NMR CDC13 6 1.57 9H, s , 3.93 4.47 2H, m , 5.57 1H, d, J 5.5Hz , 6.13 1H, d, J 2.0Hz , 7.27 1H, s , 7.85 4H, m IR cm 1max CDCl3 2100, 1800, 1790, 1730, 1630Example 38 Preparation of tertiary butyl ester of cis7ss amino 4ss azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2carboxylic acid EMI56.1 Reaction and extraction are carried out in the same manner as in Example 32 with 20 g of tertiary butyl ester of cis 7ss phthalimido 4ss azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid, whereby 560 mg of the desired compound is obtained as oily matters. The oily matters are used in the next step without silica gel chromatographic purification. Yield 41.0 . NMR CDCl3 1.57 9H, s , 3.77 4.60 3H, m 6.08 1H, d, J 2.5Hz IR maxcm 1 CHCk3 2100, 1780 sh , 1775, 1720, 1630Example 39 Preparation of i cis 78 amino 4B azido l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid trifluoroacetate EMI56.2 Reaction and purification are carried out in the same manner as in Example 33 with 560 mg of tertiary butyl ester of cis 7ss amino 4ss azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid, whereby 336 mg of the desired compound is obtained as powder. Yield 49.7 . NMR d6DMSO 6 3.99 3H, s , 4.57 2H, m , 6.18 1H, d, J 2.5Hz 1 IR maxcm KBr 1810 sh , 1805, 1620, 1550 Example 40 Preparation of sodium cis 7ss phenylacetamido 4ss azido 1 azabicyclo 4,2 num 0 oct 2 en 8 oxo 2 carboxylate EMI57.1 At first, 413 mg of cis 7B amino 4B azido l azabicyclo 4 ,2,0 oct 2 en 8 oxo 2 carboxylic acid trifluoroacetate is dissolved in 40 ml of aqueous 50 tetrahydrofuran, and sodium hydrogen carbonate powder is addeathereto under ice coolig and stirring to adjust the pH of the solution to. 7.5.A solution consisting of 1.1 ml of phenylacetyl chloride and 5 ml of tetrahydrofuran is added dropwise to the mixture at the same temperature, while keeping the pH to 7.2 7.5 with aqueous 50 sodium hydrogen carbonate during the reaction. The mixture is further stirred at the same temperature for one hour, and then tetrahydrofuran is distilled off under reduced pressure. The resulting aqueous solution is washed twice with ethyl acetate, and the aqueous layer is adjusted to pH 1.5 with 1N hydrochloric acid and extracted three times with ethyl acetate. After the solvent is distilled off under reduced pressure, the residue is dissolved in aqueous 50 methanol, and the solution is adjusted to pH 7.8 with a saturated aqueous sodium hydrogen carbonate solution. Then, methanol is distilled off under reduced pressure.The resulting aqueous solution is passed through a column of 40 ml of Diaion HP 20 AG resin, and the column is washed with 100 ml of water. Fractions containing the desired compound, which are eluted with watermethanol 8 1 , are joined together and concentrated under reduced pressure to obtain v72 mg of the desired compound as powder. Yield 61.1 . NMR CD3OD CDCl3 1.67 1H, m , 2.07 1H, m , 3.57 2H, s , 3.97 1H, m , 4.27 lH, m , 5.23 1H, d, J 5.0Hz , 5.97 lH, d, J 2.OHz , 7.27 5H, s 1 IR cmmax KBr 2110, 1785, 1775, 1765, 1670, 1650, 1605Example 41 Preparation of 4R,6R,7S 7 amino 4 azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI58.1 41 1 Preparation of cell fracture liquor a Culturing of microorganism having an optically selective, deacylating property As a seed microorganism, Kluyvera citrophilaATCC 21285 is used whose bacteriological.properties are disclosed in J. General Applied Microbiology 3, 28 31 1957 1. An aqueous solution containing 1 polypeptone, 1 yeast extract, 0.5t meat extract, 0.5 sodium glutamate and 0.258 sodium chloride, adjusted to pH 7.0 with 5N NaOH is used as a seed medium. One loopful of the seed microorganism is inoculated in 10 ml of the seed medium in a 50 ml large test tube, and cultured with shaking at 300C for 24 hours. The total amount of the seed medium is inoculated in 300 ml of a fermentation medium in a 2 Q ribbed Erlenmeyer flask and culturing is carried out with shaking at 300C. The fermentation medium has the same composition as that of the seed medium. b Preparation of cell fracture liquor Cells are recovered from the fermentation liquor by centrifugation after 24 hours of the fermentation culturing, and washed twice with 50 ml of an aqueous 0.9 sodium chloride solution. The cells are suspended in a 1 30 M phosphate buffer. The cell concentration is 40 mg ml, where the cell weight is based on dried cells. Then, lb ml of the suspension is placed in a 50 ml large test tube and subjected to ultrasonic treatment with 200 watts to fracture the cells, whereby a cell fracture liquor is prepared. The ultrasonic treatment is carried out by an ultrasonic generator Model UR200P, made by Tomy Seiko Co., Ltd., Japan.41 2 Preparation of substrate solution At first, 270 mg of sodium 76 phenylacetamido 4a azido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate is added to 9 ml of a 1 30 M phosphate buffer pH 6.5 .The compound fails to dissolve at that time, but dissolves by adding thereto 2N NaOH by small portions and readjusting the pH to 6.5. Ultimately, deionized water is added thereto to maka the volume 10 ml.41 3 Enzyme reaction At first, 10 ml of said cell fracture liquor is added to 10 ml of the substrate solution, and then, enzyme reaction is carried out at 300C for 80 minutes.41 4 Isolation and purification After the end of the reaction, cells are removed from the reaction mixture by centrifugation, and the supernatant is adjusted to pH 3.0 with 1N hydrochloric acid.The resulting crystals of the desired compound are separated by filtration 27 mg . The filtrate is charged onto a column filled with 200 ml of Diaion HP 10 resin, and fractions containing the desired compound, which are eluted with water, are joined together, concentrated under reduced pressure and freeze dried to obtain 26 mg of white powder.By joining together, 53 mg of the desired compound is obtained. Yield 63.9 . a 22 141.8c c 0.65, 50 aqueous tetrahydrofuran D adjusted to pH 8.0 with triethylamine NMR d6DMSO D2O 1.51 2.43 2H, m , 3.83 1H, m , 4.41 1H, d, J 5.9Hz , 4.50 lH, m , 5.98 lH, d, J 2.0Hz IR maxcm 1 KBr 2200, 1800, 1790 sh , 1780 sh , 1620, 1550Example 42 Preparation of tertiary butyl ester of i cis 7ss phthalimido 4 alpha methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI60.1 At first, 62 ml of anhydrous carbon tetrachloride, 0.59 g of N bromosuccinimide and 0.19 g of azobisisobutyronitrile are added to 1.23 g of tertiary butyl ester of t cis 7ss phthalimido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2carboxylic acid, and the mixture is refluxed with heating and stirring for 40 minutes. Then, the reaction mixture is cooled to 700C, and 10 ml of anhydrous methanol is added thereto. The mixture is refluxed with heating for 20 minutes. The reaction mixture is concentrated under reduced pressure, and 5 ml of ethyl acetate, 10 ml of ether and 15 ml of n hexane are added to the residue. The deposited crystals are separated by filtration, whereby 0.87 g of the desired compound is obtained. Yield 65.5 . Physical properties of the compound are given below 1 IR maxcm KBr 1800 sh , 1795 sh , 1780, 1735, 1725 sh NMA CDC13 6 7.82 4H, m , 6.40 1H, d, J 5Hz , 5.70 1H, d, J 6Hz , 3.87 4.20 2H, m , 3.37 3H, s , 1.1 2.2 2H, m , 1.57 9H, 5 Example 43 Preparation of cis 7ss phthalimido 4 alpha methoxy 1 azabycyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI61.1 At first, 150 mg of tertiary butyl ester of t cis 7ss phthalaimido 4 alpha methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 2 ml of anhydrous methylene chloride, and 2 ml of trifluoroacetic acid is added thereto.The mixture is allowed to stand at room temperature for one hour. The reaction mixture is concentrated under reduced pressure, ethyl acetate is added thereto, and the mixture is re concentrated under reduced pressure.The residue is washed with ether, whereby 119 mg of the desired compound is obtained as white powder. Yield 92.0 . IR maxcm KBr 1805 sh , 1800, 1790, 1730 sh , 1725 NMR CDC13 CD3OD 7.85 4H, m , 6.55 1H, d, J 5HZ, 5.75 1H, d, J 5.SHz , 3.9 4.3 2H, m , 3.40 3H, s , 1.2 2.3 2H, m Example 44 Preparation of cis 7 B amino 4 a methoxy l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI61.2 At first, 119 mg of cis 7ss phthalimido 4 alpha methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 1.9 ml of an aqueous 0.2N sodium hydrogen carbonate solution, and a solution consisting of 30 1 of hydrazine hydrate and 270 p1 of water is added thereto under ice cooling over 15 minutes. The mixture as such is subjected to reaction for one hour. The reaction mixture is adjusted to pH 1.5 with 1N hydrochloric acid, and the mixture is stirred at room temperature for two hours. The deposited crystals are removed by filtration, and the filtrate is adjusted to pH 3.5 with 0.2N aqueous sodium hydrogen carbonate. The solution is then concentrated to 2 ml under reduced pressure, and purified twice with 30 ml of Diaion HP 10 resin.Fractions containing the desired compound, which are eluted with water, are joined together, and the solvent is distilled off under reduced pressure to obtain 52 mg of white powder. Yield 70.5 . IR maxcm 1 KBr 1800, 1790 sh , 1620, 1540 1590 max NMR D2O 6.23 1H, d, J 5.4Hz , 4.92 1H, d, J 5.4Hz , 3.9 4.3 2H, m , 3.47 3H, s , 2.3 2.5 lH, m , 1.71 1H, ddd, J 13.8, 4.2, 3.9Hz Example 45 Preparation of sodium cis 7B phenslacetami o 4a methoxy l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate EMI62.1 At first, 420 mg of cis 7ss amino 4 alpha methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 80 ml of an aqueous 505 tetrahydrofuran, and the solution is adjusted to pH 7.5 under ice cooling and stirring by adding powder of sodium hydrogen carbonate thereto.Then, a solution of 2.3 ml of phenylacetyl chloride in 7 ml of tetrahydrofuran is added dropwise thereto at the same temperature, while keeping the pH of the reaction solution at 7.3 7.5 with a saturated aqueous sodium hydrogen carbonate solution. The mixture is stirred at the same temperature for one hour, and the precipitate is removed by filtration. The filtrate is concentrated under reduced pressure to distill off tetrahydrofuran.The residue is washed twice with ethyl acetate, and the aqueous layer is adjusted to pH 1.5 with 1N hydrochloric acid and extracted three times with ethyl acetate. After the solvent is distilled off, the residue is dissolved in methanol, and the solution is adjusted to pH 7.8 with a saturated aqueous sodium hydrogen carbonate solution.Then, methanol is distilled off under reduced pressure. The resulting aqueous solution is passed through a column with 200 ml of Diaion HP 10 resin, and the column is washed with .500 ml of water. Fractions containing the desired compound, which are eluted with water methanol 10 1 V V , are joined together, and the solvent is distilled off under reduced pressure. The residue is vacuum dried in the presence of phosphorus pentoxide to obtain 480 mg of the desired compound as white powder.Yield 72.18. Physical properties of the compound are given below IR 1 IR vmax sBr 1770 sh , 1760, 1660, 1600 NMR CD30D 6 7.30 5H, brs , 6.23 1H, d, J 5.5Hz , 5.35 1H, d, J 5.4Hz , 3.7 4.0 2H, m , 3.60 2H, s , 3.37 3H, s , 1.80 2.17 1H, m , 1.27 1.67 1H, m Example 46 Preparation of 4S,6R,7S 7 amino 4 methoxy l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI64.1 46 1 Preparation of cell suspension 46 2 Preparation of substrate solution 46 3 Enzyme reaction The same procedures as in Reference Example 41 1 , 41 2 and 41 3 are carried out except that 480 mg of sodium Y cis 76 phenylacetamido 4a methoxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylate is used.46 4 Isolation and purification After completion of the reaction, cells are removed from the reaction mixture by centrifugation, and the supernatant is adjusted to pH 3.0 with 2N hydrochloric acid.Then, the reaction mixture is charged onto a column filled with 200 ml of Diaion HP 10. Fractions containing the desired compound, which are eluted with water, are joined together, concentrated under reduced pressure, and freezedried to obtain 107.7 mg of white powder. Yield 71.1 . Physical properties of the compound are given below alpha 20 D 86.0 c 0.25, 1 M phosphate buffer, pH7 IR and NMR spectra thereof are the same as those of the corresponding dl isomer. Reference Example 1 Preparation of diphenylmethyl ester of 4S,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminOacetamido 4 hydroxy 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI65.1 At first, 1.93 g 2.98 m moles of diphenylmethyl ester of 4S,6R,7S 7 2 2 tritylamino 4 thiyzolyl 2 syn methOxyiminOacetamido 4 hydroxy 1 azabicyclo 4,2,0Zoct 2 en 8 oxo 2 carboxylic acid is dissolved in 150 ml of water, and 100 ml of ethyl acetate is added thereto. Then, 2N hydrochloric acid is added thereto to adjust Ehe aqueous layer to pH 2. After separation of the ethyl acetate layer, the aqueous layer is extracted four times with 50 ml of ethyl acetate. The organic layers are joined together, washed with a saturated aqueous sodium chloride solution and dried over sodium sulfate. The layer is concentrated under reduced pressure to about 70 ml, and 3 0 ml of chloroform is added thereto. Diphenyldiazomethane is added thereto until it is not discolored. After stirring for 7.5 hours, deposited crystals are separated by filtration, and washed with ether, whereby 880 mg of yellow powder is obtained. The filtrate is concentrated under reduced pressure, and purified by silica gel column chromatography.The column is developed with n hexane ethyl acetate 1 1 , and fractions containing the desired compound are joined together, and concentrated under reduced pressure to obtain 1.12 g of yellow powder. By joining it with 880 mg of the former powder, 2.00 g 2.53 m moles of the desired compound is obtained. Yield 85.0 . NMR CDCl3 7.5 7.0 27H, m , 6.95 1H, s , 6.56 1H, s , 6.50 1H, d, J 5.4Hz , 5.43 1H, dd, J 5Hz, 5Hz , 4.35 1H, m , 4.10 1H, m , 3.96 3H, s , 1.7 1.2 2H, m IR ,cm1 max CHCl3 1795, 1782, 1735, 1685 Reference Example 2 Antibacterial effects of the present compounds by dilution method on Mueller Hinton agar are shown in the following table MIC g ml .EMI66.1 tb Micro SEP Compound SEP Compound SEP Compound SEP Compound SEP Compound SEP Compound tb organism SEP of SEP Exs. SEP of SEP Ex. SEP 6 SEP of SEP Ex. SEP 13 SEP of SEP Ex.15 SEP of SEP Ex.23 SEP of SEP Ex.26 tb SEP 5 SEP and SEP 17 tb SEP 1 SEP 1.56 SEP 3.13 SEP 3.13 SEP 6.25 SEP 3.13 SEP 6.25 tb SEP 2 SEP 0.1 SEP 0.05 SEP 0.78 SEP 0.1 SEP 0.39 SEP 0.05 tb SEP 3 SEP 0.02 SEP 0.02 SEP 0.39 SEP 0.02 SEP 0.2 SEP 0.02 tb SEP 4 SEP 6.25 SEP 0.05 SEP 6.25 SEP 6.25 SEP 25 SEP 6.25 tb SEP 5 SEP 0.01 SEP 0.02 SEP 0.01 SEP 0.01 SEP 0.01 tb SEP 6 SEP 0.01 SEP 1 SEP 0.05 SEP 0.78 SEP 0.0l SEP 0.2 SEP 0.02 tb SEP 7 SEP 0.01 SEP 0.2 SEP 0.01 SEP 0.02 SEP 0.01 tb SEP RTI ID 66.8 3 SEP 25 SEP 3.13 SEP 50 SEP 50 SEP 50 SEP 25 tb 6.25 SEP 0.1 SEP 12.5 SEP 12.5 SEP 12.5 SEP 12.5 tb SEP 10 SEP 12.5 SEP 0.02 SEP 25 SEP 25 SEP 12.5 SEP 25 tb SEP 11 SEP 100 SEP 25 SEP 100 SEP 100 SEP 100 SEP 100 tb 1 Staphilococcus aureus 209 P 2 Escherichia coli NIHJ C 2 3 Krebsiella pneumoniae 8045 4 Serratia marcescens T 26 5 Proteus vulgaris 6897 6 Proteus morganii 4298 7 Proteus rettgeri 4289 8 Enterobacter aerogenes F 1948 9 Pseudomonas aerginosa 145 10 Pseudomonas sepatia F 2251 11 Pseudomonas maltphilia F 3438 Reference Example 3 Preparation of tertiary butyl ester of t cis 7ss phthalimido 1 azabicyclo 4,2,0 oct 2 en 8 oXo 2 carboxylic acid EMI67.1 3 1 Preparation of tertiary butyl ester of cis 4 3,3 dimethoxy l propen l yl 3 phthalimido 2 oxoazetidin l yl a diethyl2hosphonoacetic acid At first, 20 g 74.8 m moles of tertiary butyl ester of a amino a diethylphosphonoacetic acid is dissolved in 160 ml of ethyl acetate, and 11.43 g 52.3 m moles of 4,4 dimethyl trans 2 butenal is added to the solution.The mixture is heated at 500C for 10 minutes. The solvent is distilled off at a bath temperature of 50 C under reduced pressure, whereby a Schiff base is obtained as oily matters.Then, 250 ml of anhydrous methylene chloride is added to the oily matters, and 12.7 ml 89.8 m moles of triethylamine is added to the resulting solution under ice cooling and stirring. A solution of 18.4 g 82.3 m moles of phthalylglycinyl chloride in 60 ml of methylene chloride is added dropwise to the reaction mixture over one hour.After the dropwise addition, the ice water bath is removed, and the mixture is stirred as such to room temperature for 2 hours. Then, the insoluble matters are removed from the reaction mixture by filtration, and the filtrate is washed with 100 ml of a saturated aqueous sodium chloride solution, twice with a solution consisting of 25 ml of a saturated aqueous sodium hydrogen sulfite solution and 25 ml of water, and then twice with a saturated aqueous sodium chloride solution. The organic layer is dried over anhydrous sodium sulfate, and the solvent is distilled of to obtain 46 g of oily matters hereinafter referred to as crude acetal compound .The crude acetal compound is purified by silica gel chromatography Wako gel C 200 2 i, elution with n hexane ethyl acetate 1 2 V V , whereby 31.8 g of the desired compound as a mixture of about 1 1 diasteromers is obtained as crystalline oily matters.Yield 75 . NMR CDC13 6 1.30 1.53 15H, m , 2.98 3 2H, s , 3.01 3 2H, s , 3.08 3 2H, s , 3.10 3 2H, s , 4.06 4.41 4H, m , t.61 1 2H, d, J 5Hz , 4.62 1 2H, d, J 5Hz , 44.81 5.04 1H, m , 4.99 1 2H, d, J 24Hz , 5.02 1 2H, d, J 24Hz , 5.51 5.74 2H, m , 5.9 6.2 1H, m , 7.68 7.92 4H, m IR maxcm 1 CHCl3 1790 sh , 1780, 1775, 1730 3 2 Preparation of tertiary butyl ester of cis 4 3 oxol propen l yl 3 phthalimido 2 oxoazetidin l yl a diethylphosphonoacetic acid At first, 7.1 g of p toluenesulfonic acid monohydrate is added to a solution of 46 g of the crude acetal compound obtained in 3 1 in a mixed solvent of 400 ml of methylene chloride and 20 ml of acetone, under ice cooling and stirring, and the mixture is stirred as such for one hour and a half. Then, water is added to the reaction mixture, and the organic layer is washed with water, twice with a saturated aqueous sodium chloride solution, once with a saturated aqueous sodium hydrogen carbonate solution and three times with a saturated aqueous sodium chloride sblution.The organic layer is dried over anhydrous sodium sulfate, and the solvent is distilled off to obtain 35 g of oil matters hereinafter referred to as crude aldehyde compound . The crude aldehyde compound is purified by silica gel chromatography Wako gel C 200 600 ml, elution with n hexane ethyl acetate 1 1 V V , whereby 28.3 g of the desired compound as a mixture of diasteromers is obtained as crystalline oil matters. Yield 72.7 . Physical properties of the compound are given below IR maxcm 1 CHCl3 1790 sh , 1780, 1730, 1695 NMR CDC13 6 9.5 1H, d, J 8.0Hz , 7.8 4H, br 6.9 7.4 1H, m , 5.9 6.3 1H, m , 5.7 1H, m 5.1 1H, d, J 23Hz , 4.0 4.5 5H, m , 1.5 9H, s , 1.4 6H, t, J 7Hz 3 3 Preparation of tertiary butyl ester of cis.7ss phthalimido 1 azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid At first, 60 g of tertiary butyl ester of cis 4 3 oxo l propen l yl 3 phthalimido 2 oxoazetidin l yl a diethylphosphonoacetic acid obtained in 3 2 is dissolved in 600 ml of dimethoxyethane, and 30 g of 5 palladium carbon is added thereto. Then, a hydrogen gas is introduced in the mixture at 400C with stirring for 3 hours. After completion of the reaction, the catalyst is removed by filtration, and 20 g of diazabicyclooctane is added to the reaction mixture. The mixture is allowed to stand at room temperature overnight. Then, 1 2 of chloroform is added to the reaction mixture, and the mixture is washed with dilute hydrochloric acid and water, and concentrated under reduced pressure. The residue is treated with ethyl acetate, whereby colorless needle like crystals are obtained. By filtration, 29.6 g of the desired compound is obtained.Yield 70 . Physical properties of the compound are given below 1 IR cm CHCl3 1800, 1780, 1735, 1635 max 3 NMR CDCl3 7.82 4H, m , 6.35 1H, m , 5.64 1H, d, J 5.0Hz , 3.88 1H, m , 1.67 2.58 4H, m , l.57 9H, s Reference Example 4 Preparation of 4S 6R,75 7 2 2 aminothiazol 4 yl 2 syn methoxyiminoacetamiao 4 acetoxy l azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI70.1 At first, 20 g 31 m moles of sodium tS,6R,7S 7 2 2 tritylamino 4 thiazolyl 2 syn methoxyiminOacetamido 4 hydroxy 1 azabicyclot4,2,0 oct 2 en 8 oxo 2 carboxylate prepared in the process of Example 13 of Japanese PublishedPatent Application No. 118084 81 is suspended in 600 ml of pyridine, and 29.3 ml 310 moles of acetic anhydride is added thereto. The mixture is stirred at room temperature for 3.5 hours. Then, 10 ml 106 m moles of acetic anhydride is further added thereto, and the mixture is further stirred at room temperature for 8 hours. The reaction mitre is concentrated under reduced pressure, and subjected twice to azeotropic distillation with toluene.Then, 600 ml of ether is added thereto, and the deposited precipitate is recovered by filtration, washed wIth ether and dried to obtain 21.2 g of yellow powder. The yellow powder is suspended in 500 ml of aqueous 50 acetic acid, and the suspension is stirred at 50 C for 1.5 hours, Then, the reaction mixture is concentrated under reduced pressure, and subjected twice to azeotropic distillation with water.The residue is dissolved in cimethylsul oxide, and purified with 650 ml o Diaion HP 10 resin. After washing with 1700 ml of water, 1350 ml of water methanol 8 1 , 1200 ml of water methanol 5 1 and 1200 ml of water methanol 3 1 , fractions eluted with water methanol 2 1 are joined together, and concentrated under reduced pressure.The residue is dissolved in 150 ml of methanol, and 600 ml of ether. is added to the solution. The deposited precipitate is separated by filtration, washed with ether and vacuum dried to obtain 8.34 g 19.7 m moles of the desired com pound as yellow powder. Yield 63.6 . NMR CD30D 6 6.84 1H, s , 6.37 1H, d, J 5.1Hz 5.61 1H, d, J 5.4Hz , 5.6 5.2 1H, m , 4.1 3.9 lH, m , 3.96 3H, s , 2.07 3H, s , 2.1 1.8 2H, m IR cm l IR vmmax KBr 3500, 1780, 1675, 1650 Reference Example 5 Preparation of 2 2 tritylamino 4 thiazolyl 2syn 3,4 diacetoxybenzoyloxyimino acetic acid EMI71.1 The compound is prepared according to the following steps 1 3 . 1 Preparation of diphenylmethyl 2 2 tritylamino4 thiazolyl 2 syn hydroxyiminoacetate At first, 8.58 g of 2 2 tritylamino 4 thiazolyl .2 syn hydroxyiminoacetic acid is suspended in 100 ml of tetrahydrofuran, and diphenyldiazomethane is added thereto at room temperature with stirring until the red color of the reaction mixture does not disappear. Then, 1 ml of acetic acid is added thereto, and the mixture is diluted with ethyl acetate. The organic layer is washed with a saturated aqueous sodium chloride solution, a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution in this order, dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude ester.The ester is purified by silica gel chromatography Wako gel C 100 made by Wako Junyaku Co.,Ltd., Japan , elution with n hexane ethyl acetate 3 1 V V , whereby 6.07 g of the ester is obtained. Yield 51 . NMR CDC13 6 7.13 25H, m , 7.07 1H, s , 6.10 1H, s 2 Preparation of diphenylmethyl 2 2 tritylamino 4thiazolyl 2 syn 3,4 diacetoxybenzoyloxyimino acetate At first, 910 mg of diphenylmethyl 2 2 tritylamino 4 thiazolyl 2 syn hydroxyiminoacetate is dissolved in 10 ml of anhydrous methylene chloride, and 0.230 ml of triethylamine is added thereto under ice cooling and stirring. Separately, 385.6 mg of 3, diacetoxybenzoic acid is suspended in 3 ml of anhydrous methylene chloride, 337 mg of phosphorus pentachloride is added to the suspension with stirring to undergo reaction for 30 minutes, and the mixture is concentrated under reduced pressure to obtain an acid chloride. The acid chloride is added to the first mixture, and the mixture is subjected to reaction for one hour, and then diluted with 20 ml of chloroform, washed with a saturated aqueous sodium hydrogen carbonate solution, water and a saturated aqueous sodium chloride solution in this order, dried over sodium sulfate and concentrated under reduced pressure to obtain 1.13 g of desired 3,4 diacetoxvbenzoyl compound. NMR CDC13 6 7.5 7.l 27H, m , 7.0 lH, d, J 9Hz , 6.80 1E, s , 2.30 3H, s , 2.27 3H, s 3 Preparation of 2 2 tritylamino 4 thiazolyl 2 syn 3,4 diacetoxybenzoyloxyimino acetic acid At first, 1.13 g of diphenylmethyl 2 2 tritylamino 4 thiazolyl 2 syn 3, 4 diacetoxybenzoyloxyimino acetate is dissolved in 5 ml of anhydrous methylene chloride and 5 ml of anhydrous nitromethane, and a solution of 880 mg of aluminum chloride in 4 ml of anhydrous nitromethane is added thereto dropwise under ice cooling and stirring.The reaction mixture is diluted with 50 ml of ethyl acetate 20 minutes after the dropwise addition, washed once with 1N hydrochloric acid and twice with a saturated aqueous sodium chloride solution, dried over sodium sulfate and concentrated under reduced pressure. Then, 20 ml of toluene is added to the residue, and subjected to disintegration.The toluene layer is removed by decantation, whereby 649 mg of the carboxylic acid is obtained. Then, an equivalent amount of n hexane is added to the toluene layer, and the deposited precipitate is recovered, whereby further 10q mg of the carboxylic acid is obtained. NMR DMSO d6 6 7.9 7.8 2H, m , 7.6 7.1 17H, m , 2.27 6H, s IR maxcm 1 KBr 3435, 1790, max KBr 3435, 1790, 1775 sh , 1750 sh , 1600 Reference Example 6 Preparation of 2 2 tritylamino 4 thiazolyl 2 syn 3,4 diacetoxybenzoyloxyimino acetic acid another process At first, 4.29 g of 2 2 tritylamino 4 thiazolyl 2 syn hydroxyiminoacetic acid is suspended in 50 ml of anhydrous methylene chloride, and 2.77 ml of triethylamine is added thereto under ice cooling and stirring to dissolve the acid. A solution in 10 ml of anhydrous methylene chloride of the acid chloride prepared from 2.34 g of 3,4diacetoxybenzoic acid in the same manner as in Ref. Ex. 5 2 is added dropwise to the solution. The reaction mixture is washed, one hour after the dropwise addition, once with 1N hydrochloric acid, and twice with a saturated aqueous sodium chloride solution, dried over, sodium sulfate, and concentrated under reduced pressure to obtain crude carboxylic acid. The residue is disintegrated in ether, stirred in ether overnight, and recovered by filtration, whereby 5.31 g of the desired carboxylic acid is obtained. IR and NMR of the compound are identical with those obtained in Reference Example 5 3 .Reference Example 7 Preparation of 2 2formylamino 4 thiazolyl 2 syn 3,4 diacetoxybenzoyloxyimino acetic acid EMI74.1 At first, 215 mg of 2 2 formylamino 4 thiazolyl 2 syn hydroxyiminoacetic acid and 306 1 2.2 m moles of triethylamine are dissolved in 4 ml of dichloromethane, and a solution of 256 mg 1 m mole of 314 diacetoxybenzoyl chloride in 3 ml of dichloromethane is added thereto under ice cooling and stirring. The mixture is stirred under ice cooling for 30 minutes and at room temperature for 30 minutes, and then the reaction mixture is poured into water. The mixture is adjusted to pH 1 with 10 hydrochloric acid and extracted twice with ethyl acetate. .The extract is washed with an aqueous sodium chloride solution, dried over sodium sulfate, and concentrated under reduced pressure. The residue is disintegrated to powder in ethyl acetate hexane 1 1 and recrystallized from chloroform methanol, whereby 150 mg of the desired compound is obtained. NMR DC30D 6 8.57 1H, s , 8.2 7.7 2H, m , 7.5 7.3 2H, m , 3.3 6H, s IR maxcm 1 KBr 3150 br , 1795, 1782, 1775, 1750, 1559Reference Example 8 Preparation of S 2 3,4 diacetoxybenzamido 2 2 chloroacetamido 4 thiazolyl acetic acid EMI74.2 At first, 1 ml of an aqueous 0.2N sodium hydrogen carbonate solution is added to 50 mg of S 2 amino 2 2chloroacetamido 4 thiazolyl acetic acid, and the mixture is heated to dissolve the acid and then ice cooled. A solution of 77 mg of 3,4 diacetoxybenzoyl chloride in 0.5 ml of acetone is added thereto, and the reaction mixture is adjusted to pH 7.0 7.2 with an aqueous 0.4N sodium hydrogen carbonate solution. The mixture is stirred under ice cooling for 30 minutes and at room temperature for 30 minutes, adjusted to about pH 1 with 1N hydrochloric acid, and extracted three times with ethyl acetate. The organic layers are joined together, washed three times with a saturated aqueous sodium chloride solution, and dried over sodium sulfate. After sodium sulfate is removed by filtration, the filtrate is concentrated under reduced pressure to obtain oily matters.Then, 2 ml of chloroform is added to the oily matters, and the deposited crystals are separated by filtration and dried to obtain 55 mg of the desired compound. Yield 58.5 . NMR CDCl3 CD3OD 6 7.80 7.20 3H, m , 7.13 1H, s , 5.83 1H, s , 4.23 2H, s , 2.30 6H, s Reference Example 9 Synthesis of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2amino3 acetamido 4 acetoxy 1 azabicyclot4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride EMI75.1 At first, 500 mg 1.18 m moles of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2 syn methoxyimino acetamido l azabicyclot4,2,0 oct 2 en 8 oxo 2 carboxylic acid is dissolved in 5 ml of water adjusted to pH 0.8 with 2N hydro chloric acid, and 400 mg of zinc powder is added thereto.The mixture is stirred at room temperature for 2 hours while keeping the mixture at pH 1 with 2N hydrochloric acid.After removal of the zinc powder by filtration, the filtrate is subjected to column chromatography with 60 ml of Diaion HP 10. After washing with 130 ml of water, the fractions eluted with water methanol 8 1 6 1 and colored with ninhydrin are collected and concentrated under reduced pressure to obtain 298 mg 0.64 m moles of the desired compound as yellow solid matters. NMR D2O ppm 6.90 1H, s , 6.05 l 2H, d, J 5.SHz , 6.02 1 2H, d, J 5.5Hz , 5.6 5.2 2H, m , 5.15 1H, bs , 4.2 3.8 1H, m , 2.07 3H, s , 2.2 1.3 2H, m IR KBr maxcm 1 3350, 1780 s , 1770, 1760, 1600, 1520Reference Example 10 Synthesis of 4S, 6R, 7S 7 2 2 aminothiazol 4 yl 2 3,4 diacetoxybenzamido acetamido 4 acetoxy Iazabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid EMI76.1 At first, 274 mg 0.585 m moles of 4S,6R,7S 7 2 2 aminothiazol 4 yl 2 amino acetamido 4 acetoxy 1azabicyclo 4,2,0 oct 2 en 8 oxo 2 carboxylic acid hydrochloride is dissolved in 2 ml of water and 4 ml of tetrahydrofuran, and 50 l of triethylamine is added thereto at room temperature with stirring to make pH 7.0. Then, a solution of 150 mg of 3,4 diacetoxybenzoyl chloride in 2 ml of tetrahydrofuran is added thereto, while keeping the reaction mixture at pH 6 7 with triethylamine. After stirring at room temperature for 40 minutes, 40 mg of 3,4diacetoxybenzoyl chloride is added thereto in the same manner as above. After distilling off tetrahydrofuran by concentration under reduced pressure, the residues are adjusted to pH 2 with 2N hydrochloric acid and the mixture is stirred under ice cooling for 15 minutes. The deposited yellowish white precipitates are separated by filtration, washed with water, and dried to obtain 283 mg 0.471 m mole of the desired compound as yellowish white powder. NMR CD30D ppm 7.95 7.70 2H, m , 7.30 1H, d, J 8Hz , 6.60 1H, s , 6.33 1 2H, d, J 5.5Hz , 6.30 1 2H, d, J 5.5Hz , 5.62 1 2H, s , 5.58 1 2H, s , 5.6 5.3 2H, m , 2.28 6H, s , 2.02 3H, s IR KBr maxcm 1 3300, 1785 s , 1775, 1640, 1525, 1495